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ABSTRACT 
TIMOTHY MARTIN: Regulation and roles of Ral GTPase signaling components in 
oncogenesis 
(Under the direction of Channing J. Der) 
 
Since their discovery in 1986, Ral (Ras-like) GTPases have emerged as critical 
regulators of diverse cellular functions.  Like Ras, the Ral proteins cycle between an 
inactive GDP-bound state and an active GTP-bound conformation.  Ral guanine 
nucleotide exchange factors (RalGEFs) facilitate the exchange of GDP for GTP thus 
activating the Ral proteins.  When bound to GTP, Ral can interact with an array of 
downstream effector proteins and mediate numerous biological processes.  Ral GTPase-
activating proteins (RalGAPs) catalyze the hydrolysis of the bound GTP returning Ral to 
an inactive, GDP-bound conformation.  RalGEFs function as downstream effectors of the 
Ras oncoprotein that is mutationally active in approximately one-third of human cancers.  
The RalGEF-Ral signaling network comprises the third best-characterized effector of 
Ras-dependent human oncogenesis. The two Ral isoforms, RalA and RalB, have been 
found to play key roles in both normal and tumor cell biology including regulation of 
vesicular trafficking, migration and invasion, tumor formation, metastasis, and gene 
expression.   
 Examination of the contribution of Ral GTPase signaling in colorectal cancer 
(CRC) cells found opposing roles for RalA and RalB in regulating anchorage-
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independent growth.  Specifically, RalA was necessary for anchorage-independent 
growth while RalB functioned to suppress anchorage-independent proliferation.  We 
determined that RalA and RalB utilized common and distinct effector proteins to drive 
their respective growth properties.  Lastly, we found that depletion of one Ral isoform 
resulted in the upregulation of the activity of the remaining isoform indicating that RalA 
may be a viable therapeutic target to curb the growth of CRC. 
 Previous efforts to understand small GTPase signaling has found that 
phosphorylation in the membrane-targeting region of a number of small GTPases results 
in profound changes in their signaling properties.  We found that RalB is phosphorylated 
by PKC! on serine 198 and that this phosphorylation event results in the relocalization of 
RalB from the plasma membrane to endomembranes concurrent with a change in RalB 
GTP-loading.  Phosphorylation of RalB also results in a change in RalB effector 
utilization where non-phosphorylated RalB interacting with the exocyst and 
phosphorylated RalB associating with RalBP1.  Interestingly, we found that 
phosphorylation of RalB controls vesicular trafficking and that the surface expression of 
!5-integrin is dependent upon RalB phosphorylation/dephosphorylation cycling. 
 Finally we determined that RalGAP signaling functions similar to Tsc1/2 
signaling to control the activity of mTORC1, a key regulator of cellular metabolism and 
homeostasis.  Loss of RalGAP in C. elegans resulted in decreased lifespan similar to what 
has been seen in other organisms upon Tsc1/2 loss or mTORC1 inhibition.  We found 
that RalB but not RalA could directly engage mTORC1 but not mTORC2 and that this 
association was sensitive to serum but not amino acid stimulation.  We show that RalB 
utilizes the exocyst as the key effector protein responsible for mTORC1 engagement and 
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serum stimulation results in a RalB-dependent translocation of mTORC1 to the plasma 
membrane.  Surprisingly, we found that the tumor suppressor Tsc1/2 complex also 
regulates Ral GTPase activity and that RalGAP expression can restore mTORC1 
signaling in Tsc-deficient cells.  In pancreatic cancer (PDAC) cells, where RalB is known 
to drive invasion and metastasis, loss of RalGAP signaling enhanced RalB activation and 
led to an increase in cellular invasion.  This increase in invasion upon RalGAP loss was 
blocked by treatment with the mTOR inhibitor rapamycin.  Together, these studies have 
further defined Ral signaling in Ras-driven tumor cells by identifying key signaling 
events that regulate or are regulated by Ral GTPase signaling.  This work provides a 
more in depth framework for potentially targeting Ral for the treatment of diseases 
including cancer. 
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CHAPTER 1 
INTRODUCTION 
 The Ral proteins are members of the Ras superfamily of small GTPases (Figure 1-
1A).  RalA was initially identified using oligonucleotide probes to find genes that were 
similar to Ras in a cDNA library of immortalized simian B-lymphocytes [1].  Three years 
later, screening performed on a pheochromocytoma library with RalA oligonucleotide 
probes identified RalB [2].  These two proteins were found to contain 82% sequence 
identity including identical effector binding regions comprised of switches I and II (Fig. 
1-1B) with the majority of sequence divergence occurring near the C-terminus in the 
membrane-targeting hypervariable region.  This sequence diversity present in the C-
terminus is largely the reason for the different functions attributed to RalA and RalB.  
This is likely due to this region being critical in determining subcellular localization and 
potential effector interactions of the Ral proteins.  Striking evidence for this comes from 
chimeric RalB that possesses a RalA C-terminus which shows that simply swapping the 
hypervariable region can confer RalA-like activity on RalB and vice versa [3]. 
Ral GTPases were found to be marginally transforming when assayed by 
overexpressing mutationally active Ral proteins using the conventional NIH-3T3 rodent 
fibroblast transformation assay leading to their placement below the Raf and PI3K 
effector branches on the totem pole of oncogenic Ras effector signaling [4].  Upon 
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examination in human cells, it was found that Ral GTPase signaling is the main Ras 
effector pathway necessary for cellular transformation underscoring distinct requirements 
of transformation between rodent and human cells and setting the stage for last decade of 
research into the contribution of Ral signaling to oncogenesis [5]. 
 
A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 1-1.  RalA and RalB are members of the Ras superfamily of small GTPases.  A.  
RalA and RalB (in the red circle and starred) share 82% sequence identity and belong to the Ras 
family of small GTP-binding proteins.  This family is comprised of key signaling molecules 
known to play roles in normal physiology and the pathogenesis of diseases including cancer.  B.  
Sequence alignment of RalA with RalB.  RalA and RalB share identical effector binding regions 
comprised of switch I and switch II (red).  Sequence divergence occurs in the C-terminal 
hypervariable domain involved in membrane targeting and localization.  Also shown are the C. 
elegans Ral and Rheb orthologs (Ral-1 and Rheb-1, respectively) for comparison.   
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Evolutionary conservation of Ral.  Similar to Ras, functional orthologs of Ral are found 
in Drosophila and C. elegans as well as all vertebrate species.  However, unlike Ras, no 
Ral orthologs are found in S. cerevisia or S. pombe. 
 In Drosophila Ral signaling has been implicated in cell morphology during 
development.  Expression of constitutively-active RalA in the fly eye results in a rough 
eye phenotype with altered actin organization leading to changes in cell shape during 
pupal development[6].  It was later determined that RalA signaling through JNK pathway 
led to the changes in cell shape during eye development [7].  Work done by Camonis and 
colleagues showed that instead of canonical Ras-RalGEF-Ral signaling described in 
mammalian cells, Drosophila signaling is bifurcated with Ras and the Rap small GTPase 
both binding and activating the RalGEF-Ral pathway [8].  More recently the Rap-
RalGEF-Ral signaling pathway was shown to regulate spindle orientation in drosophila 
neural stem cells. 
 In C. elegans Ras and Ral signaling is involved in vulval development [9].  The 
worm vulva is developed from 6 vulval precursor cells (VPCs) that are developmentally 
equivalent.  These VPCs can adopt one of three different cell fates: primary, secondary, 
or tertiary.  In a highly reproducible process, a gonadal anchor cell secretes EGF that 
causes the VPCs to adopt either a primary or secondary cells fate while the tertiary cells 
fuse with the surrounding epithelium.  EGF signals through a Ras-Raf pathway to 
promote primary cell fate.  Ral was found to play a role in specifying secondary cell fate 
downstream of the EGF-Ras-RalGEF signal [10].  Thus Ras can switch effector usage in 
specifying C. elegans vulval development. 
 
 4 
Ral-selective GEFs and GAPs: regulators of GDP-GTP cycling.  Like many other 
small GTPases, RalA and RalB have low intrinsic GTPase activity and families of other 
proteins regulate GTP-to-GDP cycling. Guanine nucleotide exchange factors (GEFs) 
catalyze GDP-for-GTP exchange to activate small GTPases and GTPase activating 
proteins (GAPs) help to accelerate GTP hydrolysis by small GTPases (Figure 1-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2.  Regulation of the Ral GDP-GTP cycle by RalGEFs and RalGAPs.  Ral GTPases 
are binary switches that are found in an inactive conformation when bound to GDP and an active 
effector-binding conformation when bound to GTP.  Ral guanine nucleotide exchange factors 
(RalGEFs) aid in activating Ral by facilitating GDP dissociation to allow for GTP binding.  Ral 
GTPase activating proteins (RalGAPs) interact with GTP-bound Ral and catalyze the hydrolysis 
of GTP to GDP leading to inactivation of Ral.  
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The original RalGEF to be identified was RalGDS (Ral guanine nucleotide 
dissociation stimulator) [11].  Large numbers of yeast two-hybrid screens were performed 
in the early 1990s to identify Ras effectors and these screens identified not only the Raf 
serine/threonine kinase but also RalGDS [12, 13].  RalGDS was found to catalyze 
nucleotide exchange on both RalA and RalB but not other small GTPases including 
members of the Ras, Rho, and Rab families.  Yeast two-hybrid screening of H-Ras, R-
Ras, TC21/R-Ras2, and Rit identified three additional RalGEF proteins that were named 
Rgl (RalGDS-like), Rgl2, and Rgl3 [14-16].  All four human RalGEFs contain a common 
domain architecture including an N-terminal REM domain followed by a CDC25 GEF 
domain and a C-terminal RA domain (Figure 1-3). 
 Two additional RalGEFs that lack an RA domain have also been identified [17].  
These two proteins contain PH and SH3 domains and have been termed RalGPS1 and 
RalGPS2 (RalGEFs containing PH and SH3 domains) (Figure 1-3).  The absence of an 
RA domain uncouples these RalGEFs from direct association with Ras family small 
GTPases but the PH domain has been shown to be both sufficient for membrane targeting 
and necessary for Ral activation [17].  The regulation of these RalGEFs is poorly 
understood but some evidence suggests that RalGPS2 plays a role in regulating the actin 
cytoskeleton [17].  Interestingly, both types of RalGEF proteins have been implicated in 
the cytokinesis of HeLa cells where it was found that HeLa cells require RalGPS1 and 
RalGPS2 as well as RalGDS and Rgl for proper cell division [18]. 
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Figure 1-3.  Ral guanine nucleotide exchange factors (RalGEFs).  Six known RalGEF proteins 
activate Ral GTPases.  Each RalGEF possesses a catalytic CDC25 homologous GEF domain that 
functions to dissociate GDP from Ral allowing for subsequent GTP binding by Ral and activation.  
Four RalGEF proteins possess a RA domain that can interact with active Ras proteins.  It is 
believed that this association helps to bring RalGEFs to the plasma membrane where it can 
activate Ral.  Two additional RalGEFs do not associate with Ras but instead have PH domain that 
are important for lipid binding and membrane localization.  Loss of the PH domain prevents their 
GEF activity in cells. 
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More recently the RalGAPs have been identified (Figure 1-4A)[19, 20].  These 
proteins catalyze the hydrolysis of GTP to GDP by Ral to return Ral to an inactive 
conformation.  Work done by Feig and colleagues in the early 1990s suggested that the 
RalGAP activity they identified in calf and rat cytosolic extracts could be the result of a 
complex of polypeptides in part due to the large size observed for the putative RalGAP 
protein [21].  Later, mass spectrometry experiments to identify binding partners for 
activated RalA uncovered the molecular identity of two distinct RalGAP complexes 
where each complex consists of a regulatory RalGAP! subunit and a catalytic RalGAP" 
subunit [19. 20].  The RalGAP complex has similar characteristics to the tuberous-
sclerosis (Tsc) complex composed of Tsc1/Hamartin and Tsc2/tuberin which functions as 
a GAP for the Rheb small GTPase to regulate mTOR signaling (Figure 1-4B) [22].  Two 
RalGAP" (53% total sequence identity and 83% sequence identity in the GAP domain) 
subunits have been identified and each has been shown to catalyze the GTPase activity of 
both RalA and RalB but not for other small GTPases including Ras and Rheb [19, 20].  
Additionally, Saltiel and colleagues have shown that RalGAP"2 is subject to 
phosphorylation by Akt that bears a striking resemblance to the regulation of Tsc2 [20].   
RalGAP"2 phosphorylation impairs the ability of the RalGAP complex to catalyze RalA 
GTP hydrolysis not do to altered GAP activity but because of reduced RalA interaction 
with RalGAP"2 [20]. 
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A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 1-4.  Regulation of Ral signaling by RalGAP proteins.  A.  Ral GTPases utilize two 
distinct RalGAP complexes.  Each complex consists of a common RalGAP! regulatory subunit 
that does not possess GAP activity.  Two distinct catalytic subunits, RalGAP"1 and RalGAP"2, 
possess functional GAP domains and are required for RalGAP activity.  Expression of each " 
subunit has been shown to display tissue-specific expression.  B.  Regulation of Ral by RalGAP 
resembles the regulation of Rheb by the Tsc1/2 complex.  RalGAP"2 and Tsc2 are inactivated by 
Akt-mediated phosphorylation.  Inactivation of Tsc1/2 leads to Rheb activation and an increase in 
mTORC1 signaling.  Phosphorylation of RalGAP"2 by Akt was shown to enhance Ral activation 
and increase the association of RalA with the exocyst to regulate exocytosis. 
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Ral effectors: regulators of vesicular trafficking, actin cytoskeletal organization and 
gene expression.  Like Ras and other small GTPases, Ral interacts with a number of 
effector proteins when bound to GTP (Figure 1-5). 
  
 
 
 
 
 
 
 
Figure 1-5.  Ral GTPase effectors.  Ral GTPases can interact with a number of effector proteins 
involved in various biological functions.  The interaction of Ral with the exocyst compenents 
Sec5 and Exo84 is the most understood and is involved in many of the cancer phenotypes 
associated with Ral signaling including tumor cell survival and invasion/metastasis. 
 
 
The first Ral effector identified came from yeast two-hybrid and cDNA library 
screening in the early 1990s that lead to the independent discovery of RalBP1 (Ral 
binding protein 1) [23].  In addition to binding active Ral, RalBP1 also contains a 
RhoGAP domain that has been shown to be important in regulating the activity of both 
Cdc42 and Rac implicating a role for RalBP1 in modulating the actin cytoskeleton [24].  
Screening to find interacting proteins of RalBP1 found that both Reps1 and Reps2 could 
engage RalBP1 [25].  These proteins are known to be important for endocytosis with 
Reps1 interacting with Rab11-FIP2 and Reps2 binding Epsin and Eps15 [26, 27].  Work 
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done by many groups has shown that Ral is involved in the endocytic recycling of surface 
expressed proteins including E-Cadherin and EGFR [28].  Whether or not this occurs 
through Ral-RalBP1 interaction is unclear. 
 Active Ral proteins have also been shown to interact with the large multi-subunit 
exocyst complex.  The exocyst complex is composed of eight different subunits including 
EXOC1/Sec3, EXOC2/Sec5, EXOC3/Sec6, EXOC4/Sec8, EXOC5/Sec10, 
EXOC6/Sec15, EXOC7/Exo70, and EXOC8/Exo84 [29].  Ral GTPases can interact with 
either Sec5 or Exo84 [30, 31].  The exocyst is best known for its role in regulating 
vesicular trafficking and the association of Ral with both Sec5 and Exo84 have been 
found to be important in exocytosis (Figure 1-6).  Ral has been found to regulate both the 
subcellular localization of the exocyst and the assembly of the full exocyst complex [32].  
Recent evidence suggests that Ral engages the exocyst to perform a variety of cellular 
processes beyond traditional exocytosis.  White and colleagues have found that the 
association of RalB with Sec5 is critical in the innate immune response [33].  RalB 
binding with Sec5 leads to an interaction of Sec5 with TBK1, a protein kinase known to 
regulate NF-#B signaling [33].  Intriguingly, TBK1 has recently been identified in siRNA 
screens as a synthetic lethal partner of activated K-Ras [34].  The association of RalB 
with the exocyst has also been shown to regulate macroautophagy [35].  When cells are 
grown in nutrient-rich conditions, RalB has been shown to engage Sec5 [35].  Upon 
nutrient starvation, RalB then engages Exo84 leading to an upregulation of 
autophagosome formation [35].  Autophagy has emerged as a key component of Ras-
driven transformation in a variety of cell types perhaps underlying an importance of Ras-
RalGEF signaling in tumor cell autophagy [36]. 
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Figure 1-6.  The Role of the exocyst in exocytosis.  The exocyst is an octameric complex that is 
involved in specifying specific locations for vesicle delivery.  Sec3 and Exo70 can associate with 
the plasma membrane to specify sites for exocytosis.  The rest of the exocyst is delivered on the 
exocytic vesicle along with RalA and RalB.  Ral GTPases interact with two components of the 
exocyst, Sec5 and Exo84, and this interaction is essential for exocyst complex formation and 
vesicle sorting. 
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Less characterized Ral effector signaling pathways include phospholipase D1 
(PLD1), Filamin, and ZONAB.  PLD1 is best known for its role in converting 
phosphotidylcholine to phosphatidic acid and choline in response to PKC signaling 
downstream of G-protein coupled receptor (GPCR) stimulation [37].  Recent evidence 
shows that RalA is necessary for the PLD1-mediated stimulation of mTORC1 signaling 
[38].  Additionally, the interaction of both RalA and RalB with PLD1 has been shown to 
be critical for HeLa cell cytokinesis [18].  Filamin is an important component of the actin 
cytoskeleton and is involved in actin crosslinking and lamellipodia formation [39].  The 
association of RalA with Filamin was found to be important for filopodia formation in 
Swiss-3T3 cells [40].  Lastly, active RalA has been shown to engage the transcription 
factor ZONAB (zonula occludens 1-associated nucleic acid binding protein) in a cell 
density dependent manner in MDCK cells [41].  At high cell densities, RalA engages 
ZONAB unlocking the transcription of ZONAB targets but it is unclear which genes are 
regulated [41]. 
 
Post-translational regulation of Ral by protein kinases.  An emerging theme in the 
regulation of small GTPases is the ability to be phosphorylated in their C-terminal 
membrane-targeting region.  For instance, K-Ras is phosphorylated by PKC on serine 
181 that not only alters K-Ras subcellular localization but also dramatically switches its 
function from promoting proliferation to promoting apoptosis [42].  RalA and RalB are 
phosphorylated in their divergent C-terminal membrane-targeting region by distinct 
protein kinases (Figure 1-7).   
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Figure 1-7.  RalA and RalB are regulated by distinct protein kinases.  RalA and RalB 
sequence divergence is concentrated in their C-terminal hypervariable membrane-targeting region.  
Though both RalA and RalB are modified by geranylgeranylation, each can be phosphorylated by 
distinct protein kinases.  Aurora-A and PKA phosphorylate RalA on S194 and this is opposed by 
PP2A phosphatase activity.  RalB is phosphorylated by PKC on S198.  Phosphorylation serves as 
a key signal to regulate Ral subcellular localization and function. 
 
 
 
Aurora-A kinase and PKA have been found to phosphorylate RalA on serine 194 
[43, 44].  Counter and colleagues found that phosphorylation of RalA on S194 was 
critical for RalA to promote tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) 
cells [45].  This phosphorylation event dramatically altered RalA subcellular localization 
from the plasma membrane to internal membranes where it had an enhanced interaction 
with its effector protein RalBP1 [45].  More recently, Aurora-A phosphorylation of RalA 
has been found to regulate mitochondrial fission during mitosis [46].  During mitosis 
Aurora-A phosphorylates RalA and relocalizes it to mitochondria where it concentrates 
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RalBP1 and the large GTPase Drp1 where it can promote mitochondrial fission (Figure 
1-8).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8.  RalA activity is regulated by Aurora-A kinase dependent phosphorylation.  
RalA is normally found at the plasma membrane of cells but when phosphorylated by Aurora-A, 
it relocalizes to both endosomes and mitochondria.  On endosomes, phosphor-RalA interacts with 
RalBP1 to negatively regulate Ccd42 and Rac signaling to control the actin cytoskeleton.  At the 
mitochondria, RalA recruits RalBP1 and Drp1, which is important for the proper fission of 
mitochondria that occurs during cytokinesis. 
 
 
Work by our lab and others have found that RalB is regulated by phosphorylation 
with serine 198 of RalB being a target of PKC" [47].  We found that phosphorylation of 
RalB on S198 was a key regulatory switch that alters effector association with RalBP1 
and the Sec5 component of the exocyst [47].  Phosphorylation of RalB is necessary for 
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proper exocytic vesicle trafficking and fusion at the plasma membrane and the delivery of 
surface alpha-5 integrin is regulated by dynamic RalB phosphorylation [47].  
Theodorescu and colleagues found that phosphorylation of RalB on S198 was critical in 
regulating the ability of RalB to promote the metastatic growth of bladder cancer cells in 
a nude mouse model [44]. 
 Like most small GTPases, RalA and RalB contain a lipid modified C-terminus 
that assists in membrane anchoring [48].  Both Ral proteins are modified by the addition 
of a geranylgeranyl moiety on cysteine 203 and this lipid modification is critical for both 
RalA and RalB function.  Studies by Sebti and colleagues found that RalA and RalB were 
both targets of geranylgeranyl transferase inhibitors (GGTI) [49].  They went on to show 
that GGTI treatment of pancreatic tumor cells leads to a decrease in anchorage-dependent 
and anchorage-independent proliferation and increased apoptosis [49]. 
 
Ral signaling in oncogenesis .  Since RalGEFs participate in downstream signaling from 
activated Ras proteins, it was initially assumed that mutationally activated Ral proteins 
would also lead to cellular transformation.  However, unlike active K-Ras, constitutely-
active RalA did not lead to transformation of 3T3 mouse fibroblasts indicating that Ral 
proteins may play a minor role downstream of oncogenic Ras in transformation at least in 
murine cells [4].  Work done by Counter and colleagues in immortalized human HEK 
cells and found that unlike murine fibroblasts, signaling from H-Ras through the 
RalGEF-Ral pathway was sufficient for transformation [5].  Additional support for a role 
of Ral signaling in human cancer was found with the advent of RNAi (Figure 1-9).  
White and colleagues found that RalB was critical for tumor but not normal cells for 
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survival while RalA was necessary for the anchorage-independent growth of cancer cells 
[50].  Importantly, this also marked the first time RalA and RalB were found to have non-
overlapping functions [50].  Work over the subsequent years has elucidated unique roles 
for RalA and RalB in a variety of human cancers including bladder, colorectal, melanoma, 
and pancreatic as described below. 
 
Ral and bladder cancer 
 Activating Ras mutations occur in a small percentage of bladder cancers and Ral 
activation is frequently seen in both human tissue samples and tumor cell lines [51].  
Using RNAi and overexpression of mutationally activated Ral, Theodorescu and 
colleagues found that RalA and RalB play antagonistic roles in the migratory activity of 
bladder cancer cell lines with RalA suppressing and RalB enhancing motility [52].  
Further analysis of the contribution of RalB to bladder cancer found that the 
phosphorylation of RalB on S198 was critical for the ability of bladder tumor cells to 
metastasize in a mouse tail-vein injection model [44].   
Ral effector and RalGAP signaling has also been implicated in bladder cancer.  
Depletion of RalBP1 in UMUC-3 bladder cells also leads to a reduction in metastatic 
colonization of the lung following injection into immune compromised mice [53].  More 
recently, a role for RalGAP"2 has been described in bladder cancer [54].  
Immunohistochemical staining of human bladder tumor specimens indicated a reduction 
in RalGAP"2 protein expression and reduced expression correlated with poorer survival 
[54].  Interestingly, genetic deletion of the RalGAPA2 gene results in increased bladder 
tumor invasion in a chemically-induced bladder cancer mouse model [54]. 
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Figure 1-9.  The roles of Ral GTPases in a variety of cancer phenotypes.  Ral GTPase 
signaling has been implicated in numerous properties of cancer cells.  The introduction of RNAi 
technology made it possible to describe distinct functional roles for RalA and RalB in a range of 
tumor cell types utilizing many of the techniques shown in this figure.  Tissue type specificity has 
also emerged as a common theme as not all Ral-dependent phenotypes are seen in all tumor 
derived cell lines. 
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Ral and colorectal cancer 
Oncogenic KRAS mutations occur in approximately 40-50% of colorectal cancer 
(CRC) tumors and we’ve shown Ral signaling to be a critical regulator of the anchorage-
independent growth properties of CRC tumor cells [55].  We found that RNAi-mediated 
suppression of RalA resulted in a decrease in soft agar colony growth while loss of RalB 
had the opposite effect leading to an enhancement of anchorage-independent growth [55].  
Despite RalA and RalB interacting with a common set of downstream effectors, we found 
that RalA and RalB utilize both common and distinct effector proteins in regulating CRC 
anchorage-independent growth [55].  Using well-defined mutants of Ral that are 
selectively uncoupled from either Exo84, Sec5, or RalBP1 we’ve shown that RalA 
requires Exo84 and RalBP1 binding to promote the anchorage-independent growth of 
CRC cells [55].  Conversely, RalB requires Sec5 and RalBP1 to suppress soft agar colony 
formation [55].  Intriguingly, loss of one Ral isoform was found to increase the activation 
of the alternate isoform suggesting crosstalk between RalA and RalB at least in CRC 
cells [55].  What specifically mediates this RalA and RalB crosstalk is unknown but 
could be through either enhanced RalGEF accessibility for the remaining Ral protein or a 
downregulation of RalGAP activity upon single Ral isoform depletion. 
 
Ral and Melanoma 
 N-Ras mutations occur in a small percentage (15-30%) of melanomas and Ras 
signaling through the canonical Raf-MEK-Erk MAPK pathway is well known to 
contribute to their malignant growth [56].  Recent work has found that both RalA and 
RalB are necessary for the tumorigenic growth of melanomas regardless of BRaf and N-
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Ras mutation status when injected subcutaneously in mice [57].  This study also showed 
that in a panel of human melanoma cells with diverse mutational backgrounds, there is a 
consistently high level of RalA but not RalB activation [57].  Experiments using Arf-
deficient immortalized mouse melanocytes to investigate the contributions of Ras 
downstream signaling to melanomagenesis has also indicated a role for Ral signaling [58].  
In this system, expression of the RalGEF Rgl2 with a membrane localization sequence to 
mimic Ras-RalGEF activation was sufficient to promote the anchorage-indpendent 
growth and invasion of these melanocytes similar to what is observed with oncogenic N-
Ras [58]. 
 
Ral and pancreatic cancer 
 Work by our group and others has found a key role for Ral signaling in pancreatic 
adenocarcinoma (PDAC) cells.  Human PDAC has a high frequency or activating KRAS 
mutations and Ral activation is seen in both human tissue samples and tumor cell lines 
[59].  Interestingly, activation of RalA was higher than the activation of both Erk and Akt 
in PDAC cells suggesting a critical role for the RalGEF-Ral pathway downstream of 
oncogenic K-Ras [59].  Depletion of RalA and RalB using shRNA has elucidated roles 
for RalA in anchorage-independent and tumorigenic growth and RalB in invasive and 
metastatic growth of PDAC cells [59].  PDAC cells with stable RNAi depletion of RalA 
results in reduced subcutaneous tumor formation upon injection into immune 
compromised mice [59].  These same cells expressing RalB RNAi do not form lung 
metastases post-injection into the tail-vein of nude mice [59].  In addition to playing a 
role in tumor initiation, RalA has also been shown to be necessary for PDAC tumor 
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maintenance [60].  In this study, the use of inducible RNAi to stably deplete RalA from 
established primary tumors resulted in the regression of the tumor indicating a necessity 
for persistent RalA signaling in established PDAC tumors.  There is also recent evidence 
that active K-Ras signaling to RalB but not RalA plays a critical role in the formation of 
invadopodia in PDAC cells [61].  Invadopodia are actin-rich membrane protrusions that 
are known to be involved in the secretion of matrix metalloproteases (MMP) during 
tumor cell invasion [62].  RalB requires the ability to interact with RalBP1 to mediate this 
process and RalBP1 itself is necessary for the formation of invadopodia in PDAC cells 
[61].  Surprisingly, the RhoGAP activity of RalBP1 is not necessary for invadopodia 
formation while the ATPase activity is required [61].  Why the ATPase activity is 
necessary for RalBP1 to mediate invadopodia formation is unclear. 
 RalGEFs have also been found to play a role in PDAC.  Rgl2 is overexpressed in 
PDAC patient tumors and has been shown to be necessary for both the anchorage-
independent and invasive growth of PDAC tumor cells [63].  RNAi-mediated depletion 
of Rgl2 results in a significant decrease in both RalA and RalB activation [63].  
Interestingly, expression of constitutively active RalA could not rescue soft agar growth 
after the loss of Rgl2 indicating that Rgl2 may have non-Ral regulatory functions or that 
the RalA interaction with Rgl2 is critically important for the regulation of anchorage-
independent growth [63].  Rgl2 was found to be co-localized with RalB but not RalA at 
the leading edge of migrating CFPac-1 PDAC cells and loss of Rgl2 results in a loss of 
RalB from the leading edge perhaps giving insight into how the migratory and invasive 
activity of PDAC cells relies on Rgl2/RalB signaling [63]. 
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Rationale for studies.  Oncogenic mutations in Ras proteins are found in approximately 
33% of all cancers and Ras signaling is implicated in driving both tumorigenesis and 
metastasis.  Direct antagonism of Ras has proved to be unsuccessful thusfar and efforts to 
block downstream Ras effector signaling are currently underway.  Recent evidence 
suggests a key role for RalGEF-Ral GTPase signaling network in the pathogenesis of a 
variety of cancer types.  Since oncogenic KRAS muations occur in a large percentage of 
colorectal cancer (CRC) tumors, I hypothesized that RalGEF-Ral signaling would play a 
key role in maintaining the oncogenic properties of CRC tumor cells. As discussed in 
Chapter 2, I found a striking difference in the requirements for RalA and RalB in the 
regulation of CRC tumor cell anchorage-independent growth.  Specifically, RalA was 
required for soft agar colony formation while RalB actually suppressed the soft agar 
growth of CRC tumor cells.  Interestingly, RalA and RalB required both common and 
unique effector proteins to mediate their effects on CRC anchorage-independent growth.  
More in vivo studies are needed to better characterize and address the importance of Ral 
signaling to CRC tumorigenesis and metastasis. 
 Since many other small GTPases are regulated by phosphorylation in their C-
terminal hypervariable region, I hypothesized that RalB was under similar control by an 
undetermined protein kinase.  I deemed this to be an important question due to the key 
importance of RalB signaling in regulating tumor cell survival, invasion and metastasis, 
and tumorigenesis in certain tissue types.  Analysis of the RalB hypervariable region 
across many different animal species and kinase motif prediction software identified 
Serine 198 as a potential PKC phosphorylation site.  Using phosphodeficient and 
phosphomimetic mutations, I identified S198 RalB phosphorylation as an important 
 22 
regulator of exocytosis.  I found that phosphorylation on S198 allows for a switch in the 
ability of RalB to associate with Sec5/exocyst and RalBP1 and that phosphorylation 
signals for the internalization of RalB from the plasma membrane to endomembranes.  
Future studies are needed to address whether preventing the phosphorylation of RalB will 
be therapeutically tractable to prevent RalB-driven cancer phenotypes such as invasion 
and metastasis. 
 Upon examination of the RalGAP proteins, I noticed that they were remarkably 
similar to the RhebGAP Tsc1/2 complex that is a critical modulator of mTORC1 activity.  
Upon discussions with a senior member of the lab, Dave Reiner, I learned that C. elegans 
do not possess homologs to Tsc1 or Tsc2 but do express homologs for both RalGAP 
subunits.  This led me to hypothesize that RalGAP-Ral signaling may be providing 
additional input into mTORC1 signaling similar to what is seen for Tsc1/2-Rheb.  As 
shown in Chapter 4, using RNAi in C. elegans to knockdown endogenous RalGAP 
expression we found that loss of RalGAP signaling leads to a reduction in worm lifespan 
similar to what is observed for Tsc1/2 or mTORC1 hyperactivation in other species.  In a 
mammalian system I found that RalB but not RalA can directly engage mTORC1 but not 
mTORC2 to modulate its signaling output to p70S6K, a key downstream substrate known 
to be involved in protein and lipid synthesis.  RalB required Sec5 and exocyst complex to 
interact with mTORC1 and RalB served to translocate mTORC1 to the plasma membrane 
in response to serum stimulation.  Loss of RalGAP signaling led to increases in mTORC1 
activity and a concurrent reduction in autophagy and increase in cell size.  Using these 
insights, I found that the invasion of pancreatic (PDAC) tumor cells is dependent upon 
RalGAP-RalB-mTORC1 signaling and treatment of PDAC tumor cells deficient in 
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RalGAP activity with the mTOR inhibitor rapamycin reduced PDAC cell invasion.  
Taken together, these studies have further elucidated the contribution of Ral signaling to 
the tumorigenic properties of cancer cells and provided new insights into downstream Ral 
signaling that may provide ways to therapeutically target Ral output for the treatment of 
cancer.  
  
 
 
CHAPTER 2 
Activation and Involvement of Ral GTPases in Colorectal Cancer
1
 
 
Overview 
Current approaches to block KRAS oncogene function focus on inhibition of K-Ras 
downstream effector signaling. We evaluated the anti-tumor activity of selumetinib 
(AZD6244, ARRY-142886), a potent and selective MEK1/2 inhibitor, on a panel of 
colorectal carcinoma (CRC) cells and found no inhibition of KRAS mutant CRC cell 
anchorage-independent growth. While AKT activity was elevated in KRAS mutant cells, 
and PI3K inhibition did impair the growth of MEK inhibitor-insensitive CRC cell lines, 
concurrent treatment with selumetinib did not provie additional anti-tumor activity. 
Therefore, we speculated that inhibition of the Ral guanine exchange factor (RalGEF) 
effector pathway may be a more effective approach for blocking CRC growth. RalGEFs 
are activators of the related RalA and RalB small GTPases and we found activation of 
both in CRC cell lines and patient tumors.  Interfering RNA stable suppression of RalA 
expression reduced CRC tumor cell anchorage-independent growth, but surprisingly, 
stable suppression of RalB greatly enhanced soft agar colony size and formation 
frequency.  Despite their opposing activities, both RalA and RalB regulation of 
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anchorage-independent growth required interaction with RalBP1/RLIP76 and 
components of the exocyst complex. Interestingly, RalA interaction with the Exo84 but 
not Sec5 exocyst component was necessary for supporting anchorage-independent 
growth, whereas RalB interaction with Sec5 but not Exo84 was necessary for inhibition 
of anchorage-independent growth. Our results suggest that anti-RalA-selective therapies 
may provide an effective approach for KRAS mutant CRC. 
 
Introduction 
Recent sequence analysis verified that KRAS is the most frequently mutated 
oncogene in colorectal cancer (CRC) [64, 65].  With considerable experimental evidence 
that mutant KRAS is required for the maintenance of CRC cell growth [66-68], it is 
believed that K-Ras inhibition will provide an effective therapeutic strategy for CRC.  
However, since efforts to directly block mutant K-Ras have not been met with success, 
current strategies have focused on inhibitors of Ras effector signaling [69]. 
The best studied Ras effector pathways are the Raf-MEK-ERK mitogen-activated 
protein kinase and phosphotidylinositol 3-kinase (PI3K)-AKT serine/threonine protein 
kinase effector pathways [70], with inhibitors of components of both pathways currently 
under clinical evaluation
2
. Further support for the functional role of these effectors in 
cancer growth comes from the identification of mutationally activated B-Raf [71, 72] or 
the p110! catalytic subunit of PI3K [73] in CRC. However, mouse model analyses have 
validated essential roles for other effectors in Ras-mediated oncogenesis: Ral guanine 
nucleotide exchange factor (RalGEF; RalGDS), the Tiam1 Rac-specific GEF and 
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phospholipase C epsilon (PLC!) [74-76]. Tiam1 [77] or PLC! [78] deficiency impaired 
colon tumorigenesis in APC mutant Min mice. Tiam1 overexpression has also been 
implicated in colon cancer metastatic growth [76]. These observations raise the question 
of whether inhibition of Raf or PI3K effector signaling, or another effector pathway, will 
be the most effective approach for treatment of KRAS mutant CRC. 
Recent studies established that Ral small GTPases, activated by RalGEFs, are 
critical drivers of human oncogenesis [79].  Our recent studies found more frequent 
activation of Ral, rather than the Raf or PI3K effector pathways, in KRAS mutant 
pancreatic ductal adenocarcinoma (PDAC) tissue and cell lines [3, 80]. Ral has also been 
found to contribute to the growth of cancer types where RAS mutations are seen 
infrequently [81].  
Mutated Ras stimulates RalGEF activation, which in turn stimulates formation of 
the active, Ral-GTP which then binds downstream effectors that stimulate diverse 
cytoplasmic signaling networks [79].  One of the surprising findings regarding Ral 
GTPases and cancer is the striking, sometimes opposing functions of the otherwise highly 
related RalA and RalB (82% amino acid identity) proteins.  For example, RalB but not 
RalA was found to be required for the survival of tumor but not normal cells [81]. In 
contrast, RalA was required for anchorage-independent tumor cell proliferation.  We 
showed that suppression of RalA but not RalB expression impaired KRAS mutant PDAC 
anchorage-independent and tumorigenic growth, whereas RalB, and to a lesser degree 
RalA, suppression impaired invasion and metastasis [80]. Theodorescu and colleagues 
also found distinct roles for RalA and RalB and concurrent loss of RalA and RalB were 
required to impair bladder cancer cell line growth [82].  Loss of RalA in the metastatic 
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PC3 prostate tumor cells inhibited bone metastasis but not subcutaneous tumor growth 
[83]. 
RalA and RalB interact with functionally diverse effectors.  Less clear is the role 
of specific effectors in Ral-mediated oncogenesis.  Perhaps the best-validated effector in 
tumor cell growth is the Sec5 subunit of the octomeric exocyst complex that regulates 
vesicle trafficking, where Sec5 activation of the TBK1 atypical IkappaB kinase is 
essential for tumor but not normal cell survival [33].  The second best studied Ral 
effector is RalBP1/RLIP76 that functions as a GAP for Rho small GTPases [84].  RalBP1 
overexpression has been found in a variety of tumor cells and RalBP1 inhibition 
suppressed tumor xenograft tumor growth in mice [85].  Whether these reported tumor 
promoting activities of RalBP1 are relevant for mutant Ras-activated RalGEF-Ral 
signaling has not been addressed. 
With multiple effectors implicated in K-Ras-mediated CRC growth, a key 
unresolved issue is which effector pathway(s) should be targeted for effective K-Ras 
inhibition. We utilized pharmacologic inhibition of Raf and PI3K and found variable 
effectiveness in blocking KRAS mutant CRC anchorage-independent growth.  We 
therefore explored a role for Ral GTPases and found that RalA was required for CRC 
growth, but surprisingly, suppression of RalB enhanced growth. Since we previously 
found that RalB was dispensable for pancreatic tumor cell anchorage-independent growth, 
our results demonstrate a striking difference in RalB function in two distinct mutant 
KRAS-driven cancers. Our observations suggest that anti-RalA-selective therapies may 
provide an effective approach for KRAS mutant CRC treatment. 
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Materials and Methods 
Cell culture  
Human CRC cell lines were obtained directly from ATCC and maintained in 
either DMEM-H or RPMI-1640 supplemented with 10% fetal calf serum, and frozen 
down to maintain limited passage history. All lines are reconstituted from an original 
freeze down and used for limited cell passage and discarded. Cell lines were treated with 
either selumetinib (provided by AstraZeneca) or LY294002 for 24 h for inhibition of 
ERK or AKT, and soft agar analyses were done as described previously [86].  Mutation 
status for KRAS, BRAF and PIK3CA was derived from the COSMIC database
3
.  
 
Plasmids 
Short hairpin RNA (shRNA) sequences for human RalA or RalB were subcloned 
into pSuper.retro.blast (provided by Dr. John Minna) and pSuper.retro puro 
(Oligoengine), pBabe-puro retrovirus expression vectors encoding wild-type human RalA 
and RalB and RNAi-insensitive Ral cDNA sequences for RalA or RalB have been 
described previously [80], and were used to generate cDNA sequences encoding effector 
binding mutants. shRNA sequences for human Exo84 were cloned into pSuper.retro puro 
and the sequences are as follows:  shExo84 1 – GGTGCCACTTTACTCTATA and 
shExo84 2 – ACAATATAATTTGAATGGCTAA.  RalBP1 shRNA has been described 
previously (42).  RNAi-insensitive RalBP1 was cloned into pBabeHAII puro with the 
following silent mutations (in italics): GTAGAACGTACGATGATGT.  pLKO.1 puro 
lentiviral vectors encoding Sec5 shRNA (TRCN0000116102- TRCN0000116106) were 
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obtained from OpenBiosystems TRC shRNA library and pLKO.1 puro NS shRNA 
(CAACAAGATGAAGAGCACCAA) was obtained from Sigma. 
 
Immunoblotting  
Blot analyses were done with antibodies for RalA (BD Laboratories), RalB 
(Millipore), !-actin and vinculin (Sigma), GAPDH and RalBP1 (Abcam), phosphorylated 
ERK1 and ERK2 T202/Y204, phospho-AKT S473, and total AKT (Cell Signaling), total 
ERK1/2 (Santa Cruz Biotechnology), and Exo84 (Orbigen).  A Sec5 monoclonal 
antibody was a kind gift from Dr. Charles Yeaman (University of Iowa).  Activated Ral-
GTP was determined by pull down analyses as described previously [80]. 
 
Statistical analysis  
The Fisher’s exact test was used to analyze associations between two variables 
and the Pearson Chi-square test was used to analyze association between more than two 
variables.  
 
Results 
KRAS mutant CRC cell lines are insensitive to growth inhibition by blocking MEK   
Our previous studies with two MEK1/2 inhibitors, U0126 and CI-1040 
(PD184352), found that KRAS mutation status and ERK1/2 activation (pERK) did not 
correlate strongly with MEK inhibitor sensitivity [87]. However, both inhibitors possess 
off-target activities. Therefore, we extended these analyses using a more potent and 
selective MEK1/2 inhibitor, selumetinib, that is currently undergoing extensive clinical 
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trial analyses. The majority of previous studies evaluated MEK1/2 inhibitor activity 
against tumor cell lines grown as two-dimensional anchorage-dependent cultures [88-91]. 
When compared, it was found that tumor cell growth in three-dimensional suspension 
cultures was more resistant to MEK inhibitor treatment [92, 93]. Therefore, we evaluated 
colony formation in soft agar, since this assay is widely regarded as a more accurate 
indicator of tumorigenic growth in vivo. One previous cell culture study determined that 
selumetinib inhibited pERK with a half-maximal inhibition (IC50) at a dose of <40 nM 
[87], whereas a second study found selumetinib inhibition of Raf activation of pERK in 
different cells ranging from 10 to 100 nM [91]. Therefore, we treated cells with one set 
high concentration (200 nM) to assess sensitivity, determined the degree of pERK 
reduction and evaluated its effect on growth. 
As we described previously [86], elevated pERK levels did not correlate with 
KRAS or BRAF mutation status (Figure 2-1A-C).  Similar to our previous observations 
with the U0126 and CI-1040 MEK1/2 inhibitors [86], there was wide variation in 
selumetinib treatment reduction in pERK, with some cell lines showing high sensitivity 
and others with relative insensitivity when evaluated in adherent cultures. Interestingly, 
selumentinib treatment caused limited to no inhibition of growth in all six KRAS mutant 
CRC cell lines (p=0.031) (Fig. 2-1 D). This pattern was distinct from what we observed 
with U0126 and CI-1040, where KRAS mutant SW480 growth was sensitive to both 
U0126 and CI-1040 [86].  Four of five BRAF mutant CRC lines were inhibited by 
selumetinib, with only NCI-H508 showing insensitivity.  NCI-H508 cells were also 
insensitive to U0126 and CI-1040 treatment [86].  The different activities seen with each 
MEK inhibitor may reflect different off-target activities. In contrast to other MEK 
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inhibitors, selumetinib does not exhibit inhibition of MEK5 [87, 91]. Nevertheless, 
despite inhibitor-specific differences in sensitivity, we reached the same conclusion with 
all three MEK inhibitors, that neither elevated pERK levels nor the degree of pERK 
inhibition was predictive of sensitivity to selumetinib growth inhibition. Unlike U0126 
and CI-1040 however, none of the six KRAS mutant cell lines were sensitive to 
selumetinib. 
A recent study with selumetinib and CRC cell lines found an association between 
inhibitor resistance (to DNA synthesis inhibition) and high pAKT levels [91]. Therefore, 
we determined whether MEK inhibitor refractory CRC cells lines corresponded to those 
with PIK3CA mutation and/or AKT phosphorylation and activation (pAKT).  While all 
five PIK3CA mutant CRC lines showed elevated pAKT levels, elevated pAKT was also 
seen in PIK3CA wild type cell lines (Figs. 2-1A-C) and PIK3CA mutation status did not 
correlate with selumitinib resistance (p=0.580).   Interestingly, in contrast to our previous 
findings with KRAS mutant PDAC cell lines [86], we did find elevated pAKT in all KRAS 
mutant CRC cell lines, while high pAKT levels was seen in only a subset of BRAF/KRAS 
WT (1 of 3) or BRAF mutant (3 of 5) CRC lines.  High pAKT levels had a weak 
correlation with selumetinib insensitivity (p=0.095), with some cell lines insensitive (e.g., 
COLO-320-HSR) and two cell lines, which also harbor BRAF mutations, sensitive 
(CaCo-2 and HT-29). Finally, we determined if three selumitinib insensitive KRAS 
mutant cell lines were sensitive to PI3K inhibition.  LY294002 treatment inhibited the 
growth of HCT-116, SW480, and T84 cells (~50-70%).  However, concurrent treatment 
with both LY294002 and selumetinib did not result in further inhibitory activity (Figure 
2-1E).  These results suggested that the inhibition of other Ras effector pathways, either 
 32 
alone or together with MEK and PI3K, may be required to effectively block the growth of 
KRAS mutant CRC cells. Since we recently identified a role for a third Ras effector 
pathway, leading to Ral GTPase activation, for pancreatic cancer growth [80], the 
remainder of this study focused on validating a role for Ral GTPases in CRC growth. 
 
 
 
Figure 2-1 Response of CRC tumor cells to MAPK and PI3K Inhibition. A-C, Steady state 
levels of activated pERK and pAKT, total ERK1/2 or AKT were determined by western blot 
analysis in vehicle- or selumetinib-treated cells. Blot analysis for !-actin were determined to 
verify equivalent loading of total protein. D, Colony forming activity was determined for vehicle- 
or selumetinib-treated CRC cell lines, with activity normalized to 1.0 for vehicle-treated cultures.  
E, PI3K inhibition reduces the growth of MEK inhibitor-insensitive cell lines.  Mutation status 
for KRAS or BRAF or PIK3CA is indicated; WT indicates no mutation for KRAS or BRAF.  Data 
shown are representative of two or three independent experiments. 
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RalA and RalB are activated CRC cell lines  
In our analyses of KRAS mutation positive PDAC cell lines and patient tumors, 
we determined that elevated steady-state levels of Ral GTPases, and not pERK or pAKT, 
were associated with the majority of cell lines and tumors [3, 80].  Similarly, we found 
that ERK activation did not correlate with the KRAS mutation status of CRC cell lines. 
Instead, we determined that RalA and RalB are activated persistently in CRC cell lines 
(Figure 2-2A).  In an analysis of 14 CRC cell lines, we found elevated RalA-GTP, and to 
a lesser degree, elevated RalB-GTP steady-state activity in a majority of the cell lines.  
Unlike PDAC cell lines [3], we observed concurrent and similar levels of activation of 
both RalA and RalB in the same cell lines.  The majority of KRAS mutant, as well as 
BRAF mutant, cell lines displayed Ral activation.  However, one KRAS/BRAF WT cell 
line (SNU-C1) also showed RalA and RalB activation, whereas the LS-1034 cell line 
with the weaker activating KRAS mutation (A146T) did not possess activated Ral.  Thus, 
similar to PDAC cell lines, Ral activation did not correlate strictly with KRAS mutation 
status.  Finally, we also detected activated GTP-bound RalA and RalB in CRC patient 
tumors, although there was not a consistent difference when compared to matched normal 
tissue (Figure 2-2B). However, the GTP-bound state of Ral GTPases alone is not 
indicative of activity in oncogenesis, with the phosphorylation state also being important 
[3]. 
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Figure 2-2.  Ral-GTP formation in CRC cell lines and patient tumors.  A,  Activated RalA 
and RalB expression in CRC cell lines.  Pull down analysis with GST-RalBP1-RBD was done, 
followed by blot analyses with RalA- or RalB-specific antisera.  Blot analysis of total cell lysate 
with anti-RalA or –RalB antiserum for total Ral protein, and with anti-vinculin to verify 
equivalent total protein was also done.  Data shown are representative of two independent 
experiments.  B, Activated RalA and RalB expression in CRC patient tumor tissue.  Matched 
normal (N) and tumor (T) were derived from the same patient.  Data shown are representative of 
two independent experiments. 
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RalA and RalB exhibit opposing activities in regulation of CRC cell line anchorage-
independent growth  
In our previous analyses of 9 of 9 PDAC cell lines, we found that sustained 
shRNA depletion of RalA but not RalB reduced anchorage-independent growth as 
determined by colony formation efficiency in soft agar [80].  To determine if these two 
related isoforms also served similar roles in CRC anchorage-independent growth, we 
established CRC cell lines stably-infected with the same retrovirus vector-based shRNA 
vectors used to selectively silence RalA or RalB expression as used in our PDAC studies. 
For these analyses, we evaluated KRAS or BRAF mutant or KRAS/BRAF WT 
CRC cell lines and additionally two PDAC cell lines from our previous study [80].  Mass 
populations of PDAC and CRC cell lines stably-infected with each shRNA vector were 
characterized by western blot analyses to verify steady-state reduction in endogenous 
RalA or RalB protein (Figure 2-3A and data not shown). 
 As we observed previously, suppression of RalA but not RalB reduced the soft 
agar growth of the two PDAC cell lines (PANC-1 and T3M4; data not shown).  Similarly, 
we found that RalA suppression reduced colony formation efficiency of eight of eight 
CRC cell lines, independent of KRAS mutation status (Figure 2-3B). Surprisingly, 
suppression of RalB caused a dramatic increase in colony formation efficiency for all 
eight cell lines, with a two- to three-fold increase in colonies numbers for T84 and CaCo-
2 cells.  A significant increase in colony size was also seen.  Thus, whereas PDAC soft 
agar growth was not influenced by RalB loss, for CRC cell lines, RalB exhibited a tumor 
suppressive role.    
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Figure 2-3.  RalA and RalB activity show opposing roles in regulation of CRC anchorage-
independent growth.  A, Stable suppression of endogenous RalA or RalB protein expression.  
CRC cell lines were stably-infected with pSuper.retro retrovirus vectors expressing shRNA for 
GFP (nonspecific control), RalA or RalB.  Mass populations of drug-resistant cells were 
established and blot analyses were done to verify reduction in steady-state RalA or RalB protein 
expression, and for vinculin to verify equivalent total protein. B, Suppression of RalA reduces 
whereas suppression of RalB enhances colony formation in soft agar.  Colony formation was 
quantitated after 14 days.  Data shown are representative of two independent experiments.  The 
mutation status of KRAS and BRAF is indicated with WT indicating wild type for KRAS and 
BRAF. 
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RalA and RalB have been shown to have distinct functions in a number of cellular 
processes or biological activities [81, 94, 95].  However, when concurrently suppressed, 
the phenotype associated with RalA has typically been dominant over that of RalB [81, 
82, 96].  To address this possibility, we extended our analyses to a total of six KRAS 
mutant CRC cell lines with concurrent shRNA suppression of RalA and RalB, verified 
reduction in RalA and RalB protein (Figure 2-4A) and then evaluated colony formation 
in soft agar (Figure 2-4B).  For five of six cell lines, colony formation was similar to that 
of the negative control scramble shRNA.  However, for one cell line (LS174-T), 
concurrent suppression caused a more significant reduction in colony formation than was 
seen with suppression of RalA alone. Thus, it appears that co-depletion of RalA and RalB 
reverses the RalB-depletion phenotype to a level similar to that of control shGFP. 
 Our observation that suppression of RalB enhanced CRC anchorage-independent 
growth was unexpected, since it was reported previously that transient siRNA 
suppression of RalB induced apoptosis in the SW480 CRC cell line [81] as well as in 
KRAS mutant lung tumor cell lines [34]. Our rationale for using sustained shRNA 
suppression was that we wanted to assess the consequences of prolonged antagonism of 
Ral, to more accurately model the situation that would be seen for therapeutic treatment 
of cancer. However, prolonged suppression may also allow time for compensatory 
mechanisms to arise to offset the acute consequences of RalB suppression.  One 
compensatory mechanism may involve an alteration in the activity of the Ral isoform that 
is not targeted. To address this possibility, we determined the expression and activation 
of one Ral isoform when the other isoform is suppressed by shRNA. Surprisingly, we 
found that shRNA suppression of RalA was associated with a 59- to 70-fold increase in 
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RalB-GTP levels in the two KRAS mutant cell lines.  Thus, the reduced soft agar growth 
caused by RalA suppression may be mediated by the concurrent loss of RalA function 
together with increased RalB activation.  Conversely, suppression of RalB in KRAS 
mutant cell lines was associated with a modest 1.3- to 1.5-fold increased RalA-GTP that 
may contribute to the observed increased colony formation. For the BRAF mutant HT29 
cells, a converse result was seen, where RalA suppression caused only a 2.0-fold increase 
in RalB-GTP formation, whereas RalB suppression caused a greater 9-fold increase in 
RalA-GTP formation. 
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Figure 2-4. RalA activity is dominant over RalB in regulation of CRC anchorage-
independent growth.  A, Stable suppression of endogenous RalA and/or RalB protein expression.  
CRC cell lines were stably-infected with pSuper.retro retrovirus vectors expressing shRNA for 
GFP (nonspecific control), RalA or RalB, or both RalA and RalB, and established and 
characterized as described in Fig. 2A for RalA and RalB expression.  B, Coordinate suppression 
of RalA reverses the colony formation enhancement caused by RalB suppression.  Colony 
formation was quantitated after 14 days.  Data shown are representative of two independent 
experiments.  
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RalA and RalB both utilize RalBP1, but distinct exocyst subunits, to regulate CRC 
anchorage-independent growth   
The opposing activities of RalA and RalB seen in CRC anchorage-independent 
growth suggests that these related isoforms may utilize different effectors in CRC cells.  
To address this possibility, we utilized well-characterized effector domain mutants of Ral 
that cause differential impairment in effector binding.  We first evaluated the activities of 
the D49E and D49N missense mutants, which are impaired in exocyst and 
RalBP1/RLIP76 effector binding, respectively [97-99]. It is also possible that these 
mutants are defective in binding to unknown or recently described Ral effectors such as 
ZONAB.  For these analyses, we first suppressed endogenous RalA or RalB expression 
in SW480 CRC cells, and then we compared the ability of ectopic expression of WT or 
effector binding mutant RalA or RalB to rescue the growth effects caused by loss of the 
endogenous protein (Figure 2-5A and B).  The levels of the ectopically expressed 
proteins were comparable to the endogenous levels. The reduced soft agar growth caused 
by RalA shRNA was reversed and further enhanced by ectopic expression of WT RalA 
when expressed from an shRNA-insensitive cDNA expression vector (Figure 2-5C).  In 
contrast expression of either the D49E or D49N mutant of RalA did not restore colony 
formation activity, suggesting that both the exocyst and RalBP1 contribute to RalA 
promotion of CRC soft agar growth.   
Since the D49E mutation impairs binding to both Sec5 and Exo84, we utilized a 
second set of effector binding mutants, E38R and A48W [100], to further assess which 
exocyst component was required for RalA activity.  The E38R retains the ability to bind 
RalBP1 and Exo84, but not Sec5.  The A48W mutant also retains the ability to bind 
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RalBP1 and Sec5, but is impaired in Exo84 binding.  RalA E38R but not A48W 
expression restored soft agar colony forming activity, indicating that Exo84 binding is 
important for RalA promotion of anchorage-independent growth. 
 To determine what effector(s) may be required for RalB suppression of soft agar 
growth, a similar analysis was done (Figure 2-5D).  RalB shRNA enhancement of soft 
agar growth was reversed by ectopic expression of WT RalB expressed from an shRNA-
resistant cDNA expression vector.  However, neither ectopic expression of the D49E or 
D49N mutant of RalB was able to suppress soft agar colony formation activity.  Thus, 
similar to RalA, both effectors appear to be required for RalB suppression of soft agar 
colony formation. To further delineate the role of each exocyst component, we evaluated 
the ability of E38R and A48W to reverse the colony stimulating activity of RalB shRNA.  
Ectopic expression of A48W but not E38R suppressed soft agar colony formation, 
indicating that RalB required Sec5 binding to suppress CRC anchorage-independent 
growth.  Thus, RalA and RalB utilize different exocyst subunits to regulate their 
opposing actions on CRC anchorage-independent growth. 
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Figure 2-5.  RalA and RalB require interaction with RalBP1 but distinct exocyst subunits 
for regulation of anchorage-independent growth.  A, RalA shRNA was used to suppress 
endogenous RalA expression in SW480 cells.  The cells were then infected with pBabe retrovirus 
vectors encoding WT or effector binding mutant RalA proteins encoded by an shRNA-insensitive 
cDNA sequence. B, RalB shRNA was used to suppress endogenous RalB expression in SW480 
cells.  The cells were then infected with pBabe retrovirus vectors encoding WT or effector 
binding mutant RalB proteins encoded by an shRNA-insensitive cDNA sequence.  Blot analyses 
were done with anti-RalA, anti-RalB and !-actin, to verify equivalent total protein loading.  Data 
shown are representative of two independent experiments. C, RalA and RalB require RalBP1 and 
the exocyst effector interactions to mediate their roles in CRC cell anchorage-independent growth.  
Colony formation was quantitated after 14 days.  D, RalA requires Exo84 and RalB requires Sec5 
effector interactions to regulate CRC cell anchorage-independent growth.  Colony formation was 
quantitated after 14 days.  
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Discussion 
Currently, the most promising and vigorously pursued anti-Ras approaches are 
inhibitors of the Raf-MEK-ERK or PI3K-AKT effector signaling [69]. However, these 
efforts are complicated by the likelihood that Ras-mediated oncogenesis involves the 
combined action of these and other effector pathways. In this study, we extended our 
previous evaluation of MEK inhibitors [86] to the selumetinib MEK1/2-selective 
inhibitor and concluded that KRAS mutation status but not pERK activity may be a 
marker to define selumitinib resistance in CRC. Although, pAKT activity was weakly 
associated with inhibitor insensitivity, PIK3CA mutation status was not. We also found 
Ral activation in CRC cell lines and tumors.  However, in contrast to our recent 
observations in KRAS mutant PDAC, where RalA but not RalB promoted PDAC 
anchorage-independent and tumorigenic growth, we found that RalA and RalB exhibited 
opposing roles for CRC anchorage-independent growth.  These results reveal the striking 
cell context functional differences that these GTPases may have in KRAS mutant cancers. 
Our analyses with selumetinib reached the same conclusion that we had for our 
previous study with other MEK1/2-selective inhibitors [86]; pERK activation did not 
reliably predict MEK inhibitor sensitivity. However, we did find a different pattern of 
sensitivity to selumetinib when compared to U0126 and CI-1040.  Whereas we found 
previously that a subset of KRAS mutant CRC cells did exhibit sensitivity to U0126 and 
CI-1040, we saw that all KRAS mutant CRC lines were resistant to treatment with 
selumetinib.  Perhaps this different activity reflects the more specific nature of this 
MEK1/2 inhibitor and different off-target activities of the other inhibitors (e.g., MEK5-
ERK5 inhibition).  Also, one potential caveat to our analyses is that MEK inhibitory 
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activity was determined on adherent cultures, whereas growth inhibitory activity was 
determined in nonadherent three-dimensional colonies. One recent study found that 
KRAS or BRAF mutation status did not correlate with selumetinib sensitivity, but did find 
that inhibitor resistance correlated with weak ERK and/or strong AKT activity [91].  
Consistent with their findings, we did find elevated pAKT in all KRAS mutant CRC cell 
lines and overall found a weak association of elevated pAKT with selumitinib resistance. 
Although KRAS mutant cell lines showed partial sensitivity to PI3K inhibition, we found 
that concurrent PI3K inhibition did not further enhance MEK inhibitor sensitivity.  Our 
results are consistent with another recent study that found that selumetinib response did 
not correlate with RAS mutation or PI3K activation. Instead, they identified a 13-gene 
signature that implicates the existence of compensatory signaling from RAS effectors 
other than PI3K [101].  Finally, we found that a subset of KRAS mutant pancreatic 
carcinoma cell lines are sensitive to selumetinib inhibition of soft agar growth 
(unpublished), suggesting that response to selumetinib will be tumor type dependent. 
Taken together, these results support the need to assess the importance of other effectors 
in RAS mutant cancers. 
 We previously observed a striking requirement for RalA but not RalB for the 
anchorage-independent (9 of 10) and tumorigenic growth (10 of 10) in PDAC cell lines 
[80].  In the present study, we found that RalA was also necessary for CRC anchorage-
independent growth for both KRAS and BRAF mutant cell lines.  Surprisingly, stable 
suppression of RalB caused a significant enhancement of soft agar colony size and 
colony forming efficiency. These results extend previous findings of striking functional 
differences with the related RalA and RalB isoforms [81, 82, 96], and additionally reveal 
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a significant RalB functional difference in KRAS mutant tumor cells that arise from 
different tissues. While we presently do not have a mechanistic explanation for this cell 
context difference, we speculate that it may reflect differences in RalB subcellular 
localization or posttranslational modifications, leading to different activation of effectors, 
in each tumor type.   
The different functional roles of RalA and RalB in the growth of different tumor 
types complicate the issue of whether isoform-selective or pan-Ral therapeutic 
approaches will be the most effective.  For five of six KRAS mutant CRC cell lines, we 
found that concurrent suppression of both RalA and RalB resulted in statistically 
insignificant reduction in colony formation when compared to the control shGFP cells.  
These results contrast with previous studies in different cancer types where the phenotype 
of RalA is dominant over that of RalB [81, 82, 96]. These observations argue that a 
RalA-selective therapeutic approach may be the best approach for inhibiting the growth 
of CRC and PDAC cells.  However, we also found that RalB was necessary for PDAC 
Matrigel invasion and lung colonization metastasis [80].  Whether RalB will have 
opposing actions and RalB loss will promote CRC invasion and metastasis will need to 
be established to better understand the consequences of RalA and RalB ablation for 
tumor growth in the CRC patient. 
Our results with sustained RalB suppression differ from previous studies where 
transient RalB suppression caused CRC apoptotic cell death [33, 34, 81]. When we 
evaluated transient RalB inactivation, we also observed cell death (data not shown).  We 
suspect that with sustained suppression of RalB, compensatory events may occur to offset 
the initial deleterious consequences of RalB loss.  Consistent with this possibility, we 
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observed a modest 1.3- to 1.5-fold increase in the steady-state level of RalA-GTP was 
increased by RalB suppression in KRAS mutant CRC lines that may contribute to the 
enhancement of growth.  However, we suspect that additional more significant 
compensatory events must also contribute. In contrast, we observed a 59- to 70-fold 
increase in RalB-GTP levels by RalA suppression in KRAS mutant cells. Our 
observation that steady-state expression of constitutively activated RalB impaired CRC 
growth argues that this increase contributes to RalA suppression-associated growth 
inhibition. Since it is generally accepted that targeted therapies focused on signal 
transduction molecules will require chronic therapy to maintain persistent suppression of 
target activity, we believe that our observations with sustained Ral suppression are 
relevant and important for understanding the potential consequences of Ral targeted 
therapies for CRC treatment. 
 In light of our observed opposing functions of sustained RalA and RalB depletion 
in CRC anchorage-independent growth, we were surprised to find that both RalA and 
RalB activities were dependent on RalBP1 binding.  Since RalA and RalB exhibit 
different subcellular localizations, perhaps each GTPase engages RalBP1 in spatially-
distinct locations, leading to distinct cellular outcomes.  In any case, our implication of 
RalBP1 in Ral-dependent oncogenesis contrasts with other studies where RalBP1 has not 
been involved.  Furthermore, while both RalA and RalB required association with 
exocyst components to regulate CRC growth, RalA required association with Exo84 but 
not Sec5 whereas RalB required Sec5 but not Exo84 binding (Figure 2-6).  One possible 
explanation for this result is that the differential requirements for Sec5 and Exo84 are 
unrelated to exocyst function.  Certainly for Sec5, one exocyst independent function 
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involves the TBK1 protein kinase [33]. Similarly, it was suggested that Exo84 also 
exhibits an exocyst-independent function required for growth transformation [102]. 
 In summary, our results, while supporting the value of targeting Ral GTPases for 
KRAS mutant CRC, also indicate that Ral targeted therapies may need to be tailored 
differently for different cancers.  For example, since we found that RalB was important 
for PDAC invasion and metastasis, a RalB-selective therapy may be ideally suited for 
advanced PDAC.  In contrast, a RalB-selective therapy may enhance CRC tumor growth.  
Future studies with genetic ablation of RalA or RalB in KRAS-driven mouse models of 
PDAC and CRC will provide a more comprehensive understanding of the most effective 
approach for Ral inhibition for cancer treatment. 
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Figure 2-6. Model for role and effector involvement in CRC anchorage-independent growth.  
Oncogenic K-Ras can activate RalGEFs through association with the RA domain of Ral-GEFs, 
leading to their recruitment to the plasma membrane, facilitating the activation of plasma 
membrane-bound RalA and RalB.  Active RalA interacts with Exo84 and RalBP1 to promote 
anchorage-independent growth while RalB interacts with Sec5 and RalBP1 to suppress the 
anchorage-independent growth of CRC cells.  Additionally, active RalA can negatively regulate 
the activation of RalB resulting in an enhancement in the anchorage-independent growth of CRC 
cells.  Ral and K-Ras plasma membrane association is mediated in part b posttranslational 
modification by a C20 geranylgeranyl or C15 farnesyl isoprenoid, respectively 
  
 
 
CHAPTER 3 
Phosphorylation by protein kinase C alpha regulates RalB small GTPase activation, 
subcellular localization and effector utilization
1
 
 
Overview 
Ras-like (Ral) small GTPases are regulated downstream of Ras and the 
noncanonical Ral guanine nucleotide exchange factor (RalGEF) effector pathway. 
Despite RalA and RalB sharing 82% sequence identity and utilization of shared effector 
proteins, their roles in normal and neoplastic cell growth have been shown to be highly 
distinct.  Here we determined that RalB function is regulated by protein kinase C alpha 
(PKC!) phosphorylation. We found that RalB phosphorylation on S198 in the C-terminal 
membrane targeting sequence resulted in enhanced RalB endomembrane accumulation 
and decreased RalB association with its effector, the exocyst component Sec5. 
Additionally, RalB phosphorylation regulated vesicular trafficking and membrane fusion 
by regulating v- and t-SNARE interactions. RalB phosphorylation regulated vesicular 
traffic of alpha(5)-integrin to the cell surface and cell attachment to fibronectin. In 
summary, our data suggest that phosphorylation by PKC! is critical for RalB-mediated 
vesicle trafficking and exocytosis. 
                                                
1
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Introduction 
Ral GTPases function as molecular switches that toggle between an effector 
binding GTP-bound “on” state and an inactive GDP-bound “off” state. Ral-GTP 
preferentially interacts with a spectrum of functionally distinct effectors that regulate 
diverse cellular processes such as actin cytoskeleton rearrangement, autophagy, migration 
and invasion, and vesicle trafficking [79, 103]. Despite sharing 82% sequence identity 
and interaction with a common set of effector proteins, RalA and RalB exhibit distinct 
and sometimes opposing roles in normal and cancer cell growth. For example, in 
pancreatic ductal adenocarcinoma (PDAC) cells, we determined that RalA but not RalB 
was necessary for anchorage-independent growth and tumorigenic growth in vivo  while 
RalB was instead required for invasion and metastasis in vivo [59]. In contrast, we 
showed that in colorectal carcinoma (CRC) cells, RalA was necessary to support 
anchorage-independent growth whereas RalB antagonized anchorage-independent growth 
[104]. Surprisingly, both RalA and RalB required binding to a common effector, 
RalBP1/RLIP76, to control soft agar growth, but additionally needed interaction with 
distinct components of the exocyst to support their phenotypes. RalA required interaction 
with Exo84 but not Sec5 to promote anchorage-independent growth, whereas RalB 
required association with Sec5 but not Exo84 to antagonize anchorage-independent 
proliferation.  
 One basis for the functional differences between RalA and RalB can be attributed 
to their divergent C-terminal hypervariable (HV) sequences (residues 177-202). The HV 
sequences, together with the CAAX prenylation signal motif, determines the subcellular 
localization and specific membrane association of Ral proteins, which in turn influences 
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specific effector interactions. Ral GTPases can be found at the plasma membrane or 
associated with endosomes and other endomembrane compartments. Furthermore, there 
are cell context differences in Ral localization and their activation state, and 
posttranslational modifications can dynamically regulate Ral subcellular localization [3, 
18, 45, 105]. For example, we determined that phosphorylation of S194 regulated both 
RalA subcellular localization and specific effector association, and was necessary for 
RalA to support the anchorage-independent and tumorigenic growth of PDAC cells [45].  
Furthermore, Hahn and colleagues showed that RalA S183 and S194 phosphorylation 
was regulated by the PP2A phosphatase and that this activity is necessary for the tumor 
suppressor activity of PP2A [106]. 
The RalA S183 and S194 phosphorylation sites are not found in the RalB HV 
sequence. Instead, the presence of other, evolutionarily conserved, serine residues in the 
RalB C-terminus suggests the possibility that RalB may be a substrate for other protein 
kinases. In this study, we determined that protein kinase C alpha (PKC!) phosphorylated 
RalB on S192 and S198 in the HV sequence and that S198 phosphorylation promoted 
activation of RalB and caused RalB relocalization from the plasma membrane to late 
endosomes. The novelty of our study is that we completed a systematic dissection of the 
consequences of phosphorylation, where it was necessary for RalB to engage RalBP1, 
whereas an interaction with Sec5 and the exocyst complex was negatively regulated by 
S198 phosphorylation. This phosphorylation-dependent regulation of RalB association 
with the exocyst also regulated cellular adhesion of CRC cells to fibronectin, presumably 
due to the regulation of vesicular trafficking. Specifically, RalB required a dynamic 
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phosphorylation cycle for the proper delivery of !5-integrin to the cell surface by 
regulating SNARE engagement at the plasma membrane and ultimately vesicular fusion. 
 
Materials and Methods 
Cell lines 
SW480 CRC cells were obtained from the ATCC and were maintained in RPMI-
1640 supplemented with 10% fetal calf serum (FCS).  293T cells were obtained from the 
ATCC and were maintained in DMEM-H supplemented with 10% FCS. To establish 
stably infected mass populations of cells expressing shRNA or cDNA expression vectors, 
293T cells were either transfected with pLKO.1 lentiviral or pBabe-puro retroviral 
expression constructs along with their respective packaging plasmids. Viral supernatants 
were isolated and then added to SW480 cells followed by selection in 1.0 µg/mL 
puromycin or 1.0 µg/mL blasticidin-S HCl. Bryostatin-1 (Calbiochem) treatment was 
done as indicated. 
 
 DNA constructs 
RalB retrovirus expression constructs have been described previously [104]. RalB 
cDNA sequences encoding S192 and/or S198 phosphodeficient (S to A) or putative 
phosphomimetic (S to D) mutants were prepared by site-directed mutagenesis. A 
lentiviral shRNA vector targeting human RalB was prepared by subcloning a previously 
described  shRNA sequence [104] into pLKO.1 blasticidin. An expression vector 
encoding RalB with an N-terminal mCherry (mCh) fluorescent reporter (mCh-RalB) was 
prepared by inserting the RalB cDNA sequence into pcDNA3-mCherry [107] between 
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the EcoRI and XhoI sites where the mCh DNA sequence was inserted into the BamHI 
and EcoRI sites. The TfR-mCh-SEP expression vector encodes the transferrin receptor 
tagged with both mCherry and the pH-sensitive green fluorescent protein (GFP) variant 
superecliptic pHluorin (SEP) was provided by Michael Ehlers (Duke University) and has 
been described previously [108]. PLKO.1 shRNA vectors targeting PKC! were obtained 
from the UNC-Chapel Hill lentiviral core facility with the following TRC numbers:  
TRCN0000001691 and TRCN0000001692. Full length rat PKC! has been described 
previously [109]. Full length human VAMP3 cDNA sequences were subcloned into 
pEGFP-N3 between the XhoI and HindIII sites. Full length human Sec5 was subcloned 
into pEGFP-C3 between XhoI and ApaI. Full length human RalBP1 was subcloned into 
pEGFP-C3 between the XhoI and BamHI sites. All sequences were verified by 
automated sequencing (UNC genome analysis facility). Alpha 5 integrin-GFP encodes 
human !5-integrin with a C-terminal GFP tag and was obtained from Addgene (Rick 
Horwitz; plasmid #15238) [110].  
 
Immunoprecipitations and immunoblotting 
Lysates were obtained from the indicated cell lines, were resolved by SDS-PAGE 
and transferred to PVDF filters and blotted with anti-RalB and anti-phosphoserine 
(Millipore), anti-VAMP3 (Synaptic Systems), anti-SNAP23 (Abcam), anti-Sec8 
(Stressgen), anti-"-actin (Sigma), anti-GFP (Clontech), anti-HA (Covance), anti-PKC! 
(BD biosciences), and anti-!5 integrin (Cell Signaling) antibodies. Immunoprecipitations 
were performed on lysates using 3 µg of the indicated antibodies coupled to protein G 
Dynabeads (Invitrogen). Lysates were precleared with normal mouse IgG or normal 
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rabbit IgG coupled to protein G Dynabeads for 2 h at 4°C. Precleared lysates were then 
immunoprecipitated for 3 h to overnight at 4°C. RalB-GTP activity assays were 
performed by pulldown analyses as we described previously [104]. 
 
Immunofluorescence 
Cells were grown on glass coverslips and were fixed with 4% paraformaldehyde 
in PBS. Cells were permeabilized with 0.2% Triton X-100 followed by blocking with 5% 
goat serum and 5% BSA in PBS. Primary antibodies were incubated for one h at room 
temperature followed by incubation with an Alexa Fluor-conjugated secondary antibody 
(Invitrogen) for two h at room temperature. Coverslips were mounted with Fluorsave 
(Calbiochem). Images were acquired using a Zeiss LSM 510 or Leica SP2 confocal 
microscope, and then processed using ImageJ (NIH). 
 
Live-cell imaging 
Cells were grown in 35-mm glass bottom MatTek dishes to subconfluency and 
were transfected with the indicated fluorescent constructs using Lipofectamine 2000 
(Invitrogen).  To maintain pH, prior to imaging the SW480 cells were switched to 
DMEM/F12 medium containing HEPES (Gibco) supplemented with 10% FCS.  Cells 
were kept in an environmental chamber set to 37°C (Zeiss TempControl 37-2 digital 
heater controller) and images were acquired using a Zeiss LSM 510 confocal microscope 
using sequential scanning for dual channel images. Cells were examined with an inverted 
laser scanning confocal
 
microscope (Zeiss 510 LSM) using an oil immersion 63x NA 1.4 
objective.  Images were captured by sequential scanning with the 488 nM argon and the 
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543 nM HeNe1 laser (488 nM and 543 nM for 2-color staining), and the BP 505-530 (for 
Alexa 488) and BP 585-615 (for Alexa 568 and mCherry),emission filters.  To monitor 
vesicle fusion events, TfR-mCh-SEP was transfected into subconfluent SW480 cells. 
Cells were then split onto MatTek dishes coated with 5 µg/mL fibronectin (BD 
Bioscience) and allowed to attach overnight. Single cells were imaged on a Zeiss LSM 
510 confocal microscope and images were collected every two sec. Fusion events were 
quantitated in ImageJ by applying a grid to each cell (n=10) and monitoring for an 
increase in SEP fluorescence, indicating fusion.  
 
Statistical analysis 
Data were analyzed using an unpaired t-test using Microsoft Excel and the 
Pearson's correlation coefficient was determined. Values are shown as means ± SEM. A 
p-value of <0.05 was considered significant. 
  
Results 
RalB is phosphorylated at S192 and S198 by protein kinase C alpha 
RalA and RalB share 82% overall sequence identity, with 100% sequence identity 
in the switch I and II sequences involved in effector interaction. However, the C-terminal 
HV membrane-targeting domain of RalA and RalB (Figure 3-1 A) contains the majority 
of the sequence diversity between the two proteins (~50% identity) and dictates distinct 
subcellular localization and function. RalA contains a well-conserved S194 residue that is 
a target of Aurora-A kinase phosphorylation [111]. Our recent studies showed that this 
phosphorylation site is critical for RalA to promote the anchorage-independent and 
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tumorigenic growth of pancreatic ductal adenocarcinoma (PDAC) cells [112]. To 
determine whether RalB may be similarly regulated, we performed ScanSite analyses of 
human RalB, which identified S192 and S198 (Figure 3-1A) as putative targets of protein 
kinase C (PKC) isoforms !, ", #, $ and %. To determine if S192 and S198 of RalB are 
phosphorylated in vivo, we stably suppressed endogenous RalB expression in SW480 
cells by retrovirus vector-expressed shRNA and ectopically expressed wild type or 
S192A and/or S198A point mutants of RalB from RNAi-resistant cDNA sequences 
(Figure 3-1B). Since these mutations disrupted anti-RalB antibody recognition of these 
mutant proteins, we utilized HA epitope-tagged RalB proteins for these analyses. Blot 
analyses with anti-HA and anti-RalB antibody indicated that these ectopically-expressed 
proteins were expressed at steady-state levels comparable to endogenous RalB levels. 
Mutation of S192 or S198 alone significantly reduced phosphorylation (~50%) while 
concurrent mutation (S192/198A) essentially abolished RalB serine phosphorylation 
(Figure 3-1C). Thus, both S192 and S198 are sites of steady-state phosphorylation in vivo.  
We next wanted to determine the kinase(s) responsible for RalB phosphorylation. 
Based on our ScanSite analysis we identified S198 as a putative recognition site for 
conventional (!, " and #) and novel ($ and %) PKC isoforms. To address this possibility, 
we treated SW480 cells with the conventional and novel PKC isoform activator 
bryostatin-1 to examine potential changes in endogenous RalB phosphorylation. A 
transient increase in RalB serine phosphorylation was observed 10 min post-stimulation 
with bryostatin-1 indicating that PKC activation can stimulate the phosphorylation of 
RalB in CRC cells (Figure 3-1D). Next, treatment of SW480 cells with the broadly active 
PKC inhibitor Gö6983, or Gö9676 which is selective for classical PKC isoforms, reduced 
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steady-state RalB serine phosphorylation (data not shown). These results support a PKC-
dependent RalB phosphorylation mechanism in CRC cells. 
We next wanted to identify the specific PKC isoform(s) involved in RalB 
phosphorylation. A previous study identified PKC! and PKC! but not PKC", PKC# or 
PKC$ protein expression in SW480 and other CRC cell lines [113]. Another study found 
that PKC% antagonized colonic tumorigenesis [114], consistent with RalB antagonism of 
anchorage-independent growth in CRC cells. We therefore focused on addressing a role 
for PKC% in RalB phosphorylation. To identify whether PKC! is the isoform responsible 
for RalB phosphorylation, shRNA was used to stably deplete SW480 cells of PKC!. Two 
independent shRNAs effectively knocked down endogenous PKC! without affecting the 
total levels of RalB (Figure 3-1E). Loss of PKC! expression resulted in a near-complete 
loss of RalB serine phosphorylation.  We also found that the serine phosphorylation of 
ectopically expressed RalB was abolished in PKC%-deficient but not wild type mouse 
embryo fibroblasts (data not shown). Finally, our in vitro analyses showed recombinant 
PKC% phosphorylated purified RalB in vitro, suggesting that RalB is a direct substrate of 
PKC% in vivo. We conclude that PKC% is the critical isoform involved in RalB 
phosphorylation. 
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FIGURE 3-1. RalB is phosphorylated on serines 192 and 198 and PKC!  is necessary for 
phosphorylation. A, Serines 192 and 198 are evolutionarily conserved and comprise consensus 
PKC substrate motifs. The C-terminal membrane-targeting regions of RalA and RalB were 
aligned using Clustal/W. Phosphorylation sites are bolded and the CAAX motif is underlined. B, 
Ectopic restoration of endogenous RalB expression with putative phosphodeficient or 
phosphomimetic mutants of S192 and S198. RNAi-insensitive cDNA sequences encoding HA 
epitope-tagged RalB WT or putative phosphorylation site mutants were expressed in SW480 cells. 
C, S192 and S198 are the primary sites of RalB phosphorylation in vivo. HA-tagged WT or 
phosphodeficient RalB mutants were analyzed for serine phoshporylation. D, Treatment with the 
bryostatin-1 (Bryo) PKC activator causes rapid and transient RalB serine phosphorylation in 
SW480 cells. Numbers represent the amount of pSer-RalB normalized to time zero. E, 
Knockdown of endogenous PKC! inhibits RalB steady-state phosphorylation in SW480 cells.  
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S198 phosphorylation regulates RalB activation, subcellular localization and effector 
binding   
Phosphorylation of RalA by Aurora-A [111, 112] and K-Ras4B by PKC [115] has 
been shown to alter their active, GTP-loaded state. To determine if phosphorylation could 
affect the activation state of RalB, we performed pulldown analyses to measure steady-
state levels of RalB-GTP. Mutation of S192 alone caused a limited 10% reduction in 
RalB-GTP levels, whereas mutation of S198 alone or together with S192 caused a ~50% 
reduction in RalB-GTP steady-state levels. These results suggest that the phosphorylation 
of S198 stimulates formation of active RalB-GTP (Figure 3-2A).  
Since we showed that the S198A phosphodeficient mutant showed decreased 
GTP-loading of RalB, we also determined if bryostatin-1 stimulation of RalB 
phosphorylation conversely increased endogenous RalB-GTP levels. Pulldown analyses 
identified a rapid and transient four-fold increase in RalB GTP-loading at 10 min post-
stimulation, similar to the kinetics of RalB phosphorylation, as shown in Figure 3-1D.  
We determined previously that the phosphorylation of RalA at S194 in its C-
terminal membrane targeting sequence stimulated loss of plasma membrane-associated 
RalA and increased endomembrane accumulation [112]. To examine whether the 
phosphorylation of RalB in its C-terminal membrane-targeting sequence also affected its 
localization, we compared the subcellular localization of WT and phosphodeficient RalB 
by confocal microscopy. HA-tagged WT RalB displayed significant plasma and 
endomembrane staining. Phosphodeficient RalB S192/198A was found predominantly at 
the plasma membrane while phosphomimetic S192/198D RalB was not associated with 
the plasma membrane and showed a punctate, perinuclear distribution (Figure 3-2B). To 
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determine if PKC activation and stimulation of RalB phosphorylation altered RalB 
localization, we evaluated the consequences of bryostatin-1 treatment on RalB 
subcellular localization. Bryostatin-1 treatment resulted in a loss of plasma membrane 
association and a striking enrichment to a perinuclear region (Figure 3-2C). Finally, we 
also addressed the importance of S192 and S198 phosphorylation in this translocation. 
Using GFP-tagged RalB, we found that WT but not the S198A single mutant translocated 
transiently to endomembranes upon bryostatin-1 treatment (Figure 3-2D). Taken together, 
these observations indicate that S198 phosphorylation alone regulates RalB translocation 
from the plasma membrane to internal membranes.  
To determine the specific intracellular localization of phosphorylated RalB, we 
determined if phosphomimetic S192/198D RalB showed colocalization with different 
GFP-tagged Rab GTPases that are associated with different endocytic compartments. 
Phosphomimetic RalB colocalization was observed with Rab5, Rab9, and Rab11 
indicating that phosphorylation of RalB can result in its localization to early, late, and 
recycling endosomes, respectively. 
RalB can interact with multiple effector proteins [103]. To determine if RalB 
phosphorylation and translocation to endosomes altered the association of RalB with 
effector proteins, we performed co-immunoprecipitation analyses with RalBP1 and Sec5 
in SW480 cells transiently expressing the various RalB mutants (Figure 3-2E). Similar to 
WT RalB, phosphomimetic RalB S192/198D displayed association with GFP-RalBP1. In 
contrast, phosphodeficient RalB S192/198A showed significantly reduced RalBP1 
association. In sharp contrast to the RalBP1 co-immunoprecipitation analyses, we 
observed that WT and phosphomimetic RalB S192/198D showed minimal 
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coprecipitation with GFP-Sec5, whereas phosphodeficient RalB S192/198A RalB 
displayed an enhancement in GFP-Sec5 complex formation (Figure 3-2F).  
Sec5 may be associated with exocyst function or an exocyst-independent function 
involving the TBK1 protein kinase [33]. To address this issue, we determined if RalB 
association with an exocyst subunit that cannot associate with RalB directly (Sec8) 
showed the same pattern of association. Endogenous Sec8 showed preferential co-
precipitation with S192/198A but not S192/198D (Figure 3-2G). Taken together, these 
observations are consistent with phosphorylation regulation of RalB association with and 
regulation of the exocyst complex function.  
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FIGURE 3-2.  S198 phosphorylation regulates RalB GTP-bound state, subcellular 
localization and effector interaction. A, Phosphodeficient S198A exhibits reduced GTP-loading. 
SW480 cells expressing the indicated mutants were subjected to GST-Sec5 RalBD pulldowns. 
Numbers represent the amount of RalB-GTP normalized to WT RalB. B, Phosphorylation 
mutants of RalB exhibit different subcellular localizations. SW480 CRC cells from panel A were 
fixed and RalB localization was visualized by confocal microscopy with anti-HA antibody. C, 
Bryostatin-1 treatment results in RalB endomembrane localization. SW480 cells were stimulated 
with DMSO or 100 nM bryostatin-1 for 10 min. RalB localization was visualized by confocal 
microscopy with anti-HA antibody. D, Phosphorylation of S198 regulates RalB endomembrane 
localization. SW480 cells transiently expressing GFP-tagged RalB WT or S198A were stimulated 
with DMSO or 100 nM bryostatin-1 for 10 min. E, Phosphorylation of RalB enhances RalBP1 
association. HA and GFP-RalBP1 co-IPs were performed on cells from panel A expressing GFP-
RalBP1. F, Phosphorylation of RalB is associated with decreased Sec5 association. HA and GFP-
Sec5 co-IPs were performed on cells from panel A expressing GFP-Sec5. G, Phosphorylation of 
RalB is associated with decreased Sec8 association. HA IPs were used to determine the ability of 
the indicated HA-RalB mutants to interact with endogenous Sec8. All scale bars are 20 µm. 
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RalB phosphorylation regulates vesicular fusion 
The exocyst is a large multisubunit complex involved in the polarized secretion of 
exocytic vesicles [116]. Since we observed that   RalB S192/198A and S192/198D 
showed differential association with Sec5 and the exocyst, we assessed whether the 
phosphorylation of RalB could regulate the vesicle trafficking machinery. VAMP3 
(cellubrevin) is a vesicular SNARE protein that is involved in the membrane fusion of 
exocytic vesicles [117]. Analysis of SW480 cells transiently co-expressing GFP-VAMP3 
and mCh-RalB WT found colocalization at both the plasma membrane and on internal 
vesicles (Figure 3-3A). When coexpressed with mCh-RalB S192/198A, GFP-VAMP3 
displayed a more prominent colocalization with RalB at the plasma membrane. In 
contrast, mCh-RalB S192/198D showed very little colocalization with GFP-VAMP3 at 
the plasma membrane and the majority of both proteins was found in a perinuclear region. 
These results suggest that RalB phosphorylation at S192 and/or S198 regulated 
association with VAMP3. 
The redistribution of VAMP3 upon expression of RalB phosphorylation mutants 
led us to evaluate a potential change in the association of VAMP3 with its target SNARE, 
SNAP-23. Endogenous complexes of VAMP3 with SNAP-23 were determined by 
immunoprecipitation of SNAP-23 from SW480 cells stably expressing non-specific (NS) 
or RalB RNAi to deplete endogenous RalB expression, and also ectopically expressing 
WT or phosphorylation mutants of RalB. SNAP23 was isolated by immunoprecipitation, 
followed by blot analysis to detect co-precipitating VAMP3 (Figure 3-3B). Suppression 
of endogenous RalB was associated with a 40% reduction in VAMP3 association with 
SNAP-23 that could be restored by ectopic RalB WT or phosphodeficient RalB 
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S192/198A. In contrast, phosphomimetic RalB S192/198D did not restore VAMP3 
association with SNAP23. Decreased association between VAMP3 and SNAP23 would 
result in a defect in vesicle fusion with the plasma membrane and, therefore, may be the 
underlying cause for the increased VAMP3-positive vesicles found in cells expressing 
RalB S192/198D.  
To further evaluate the role for RalB phosphorylation in vesicular traffic to the 
cell surface, we assessed whether the phosphorylation of RalB regulates the fusion of 
exocytic vesicles at the plasma membrane. For these analyses, we used a recently 
described optical sensor for the transferrin receptor (TfR), which is a widely used marker 
to monitor recycling endosomal trafficking.  TfR-mCh-SEP is a dual color reporter which 
is comprised of the TfR fused both to mCh and the superecliptic pHluorin derivative of 
GFP (SEP) [108]. Imaging the entire cellular pool of TfR can be done in the red (mCh) 
channel, whereas selective detection of TfR at the plasma membrane can be determined 
in the green (SEP) channel. Thus, this probe allows visualization of exocytic cargo before, 
during, and following membrane fusion. We monitored single exocytic fusion events at 
the plasma membrane.  Even though fusion events were observed in cells expressing WT 
as well as phosphorylation-deficient and phosphomimetic  mutants of RalB, the number 
of fusion events was decreased by ~ 70% upon expression of the phosphomimetic RalB 
S192/198D mutant when compared to WT (Figure 3-3C). These data strongly support a 
role for RalB phosphorylation in regulating the fusion of exocytic vesicles at the plasma 
membrane, potentially by regulating the dissociation of RalB from the exocyst due to 
decreased RalB-Sec5 interaction. 
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FIGURE 3-3. RalB phosphorylation regulates vesicular fusion.  
A, Phosphorylation regulates the colocalization of RalB with the v-SNARE VAMP3. SW480 
cells were transiently transfected with GFP-RalB mutants and mCh-VAMP3. Insets indicate 
colocalization of RalB with VAMP3 at the plasma membrane (“1”) and on internal membranes 
(“2”).  Scale bar represents 20 µm. B,  Phosphorylation of RalB regulates the association of 
VAMP3 and SNAP23. Endogenous SNAP23 was immunoprecipitated from SW480 cells 
expressing RalB shRNA as well as empty vector or HA-tagged RalB phosphorylation mutants. C, 
Phosphorylation of RalB regulates vesicular fusion. SW480 cells from Fig. 2-2 panel A were 
transiently transfected with the TfR-mCh-SEP expression construct to monitor vesicular fusion. 
Fusions were determined by an increase in SEP signal due to surface delivery (n=10 cells). 
Images shown are representative of independent fusion events denoted by the arrows.  Values 
shown are means ± SEM, and an unpaired t-test was used to determine significance (p<0.05). 
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Phosphorylation of RalB regulates the trafficking of !5-integrin 
The exocyst complex facilitates the targeting of secretory vesicles and their 
protein cargo to specific sites of fusion on the plasma membrane [116]. Recent work by 
Yeaman and colleagues [118] identified a role for both Sec5 and RalA/B in the delivery 
of the alpha-5 (!5) integrin subunit to the plasma membrane. Since we observed 
decreased association of Sec5 and the exocyst complex with phosphomimetic RalB as 
well as diminished SNARE complex formation and vesicle fusion events in cells 
expressing the RalB phosphomimetic mutant, we hypothesized that RalB may regulate 
the delivery of proteins to the cell surface. To determine if RalB phosphorylation is 
essential for the delivery and retention of !5 to cell surface we utilized two approaches.  
First, we used cell surface biotinylation to monitor the amount of cell surface-localized 
!5 in RalB-depleted SW480 cells stably expressing ectopic RalB WT or phosphorylation 
mutants. Suppression of endogenous RalB alone resulted in a limited (20%) decrease in 
the level of biotin-labeled !5 that was restored with ectopic RalB WT expression (Figure 
3-4A). Surprisingly, neither phosphodeficient nor phosphomimetic RalB could restore 
biotinylated !5 to levels comparable to WT RalB.  In contrast, RalB S192/198D 
expression essentially abolished surface !5 expression. In a second approach, surface or 
total levels of !5 expression were determined by anti-!5 immunofluorescence staining of 
non-permeabilized or permeabilized cells, respectively. RalB WT- and S192/198A-
expressing cells displayed predominant surface staining of !5 while RalB S192/198D 
expressing cells showed a substantial reduction in surface !5, even though total levels of 
expression were similar among all cells (Figure 3-4B). These results indicate that RalB-
mediated trafficking of !5 may require dynamic cycling between phosphorylated and 
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non-phosphorylated states to effectively transport !5 to the cell surface.  Finally, we 
determined if loss of !5 at the cell surface observed in cells expressing phosphomimetic 
RalB has biological consequences.  Cellular adhesion to fibronectin requires !5"1 
integrin; therefore we evaluated whether phosphorylation mutants of RalB cause a defect 
in this property. Consistent with the loss of surface-associated !5 integrin, adhesion to 
fibronectin of cells expressing phosphomimetic RalB was impaired as compared to WT 
RalB (Figure 3-4C).  
Since we observed that RalB colocalized with VAMP3, we also investigated the 
potential colocalization of VAMP3 with !5. Consistent with colocalization of RalB and 
VAMP3 on the vesicles, we also found VAMP3 to colocalize with !5 in SW480 cells on 
both vesicles and at the plasma membrane (Figure 3-4D). Finally, while the exocyst 
complex has been shown to be necessary for !5 trafficking [118], the co-trafficking of 
RalB with !5-containing vesicles has not been reported. To test this possibility, we co-
expressed mCh-RalB together with GFP-!5 in SW480 cells (Figure 3-4E) and 
determined co-localization by live-cell confocal microscopy. We found that the majority 
of mCherry-RalB vesicles also contained GFP-!5 and live-cell imaging of trafficking 
vesicles indicated that RalB and !5 co-traffic.  Taken together, our results suggest that 
RalB promotes trafficking and cell surface localization of !5 integrin and that 
phosphorylation of RalB by PKC! is essential for RalB function in trafficking. 
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FIGURE 3-4. Phosphorylation of RalB regulates the trafficking of ! 5-integrin. A, RalB 
phosphorylation alters !5 surface expression. Surface proteins were labeled with biotin in SW480 
cells and analyzed by western blot.  B, RalB phosphorylation regulates the surface expression of 
endogenous !5. Endogenous !5 expression from either non-permeabilized (surface) or 
permabilized (total) SW480 cells was imaged. C, Cellular attachment to fibronectin is reduced in 
cells expressing phosphomimetic RalB. SW480 cells were allowed to attach to fibronectin. 
Nonadherent cells were removed and attached cells were quantitated. D, VAMP3 and !5 
colocalize on endosomes and at the plasma membrane. Live SW480 cells expressing mCh-
VAMP3 and GFP-!5 were imaged and colocalization of VAMP3 with !5 at the plasma 
membrane (arrow) and on endosomes (arrowhead) was seen. E, RalB and !5 colocalize on 
endosomes and at the plasma membrane. Live SW480 cells expressing mCh-RalB and GFP-
!5were imaged. Line scans of the merged image indicate colocalization of RalB with !5 on both 
internal vesicles and at the plasma membrane with a Pearson’s correlation coefficient of 0.83 ± 
0.001 (SEM). Scale bar represents 20 µm. 
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Discussion 
An emerging paradigm for Ras family small GTPases is the critical importance of 
posttranslational modifications, in particular phosphorylation, in regulating their 
biological functions. An additional emerging concept is the striking functional 
differences seen in otherwise near-identical small GTPase isoforms. Our recent studies 
identified opposing roles for the highly related RalA and RalB small GTPases in the 
anchorage-independent growth of CRC tumor cells.  It has been demonstrated that RalA 
but not RalB was a substrate for Aurora-A [111] and we found that that phosphorylation 
was critical for RalA support of PDAC cell anchorage-independent growth [112].  In the 
present study, we determined that RalB is a substrate for PKC! and demonstrated the 
importance of this phosphorylation for the biochemical and cellular functions of RalB. 
We determined that PKC! phosphorylates S192 and S198 in the C-terminal membrane-
targeting region of RalB, regulating formation of RalB-GTP, plasma membrane-to-
endosome trafficking, and differential effector association. Utilizing phosphodeficient 
and phosphomimetic mutants of RalB, we determined that a dynamic cycle of 
phosphorylation and dephosphorylation regulates RalB to disengage the Sec5 component 
of the exocyst, thereby allowing for proper SNARE engagement and vesicle fusion, and 
facilitating !5 integrin surface expression and cell adhesion. Our studies thus define the 
mechanisms by which phosphorylation controls active RalB and its regulation of the 
exocyst and vesicular trafficking. 
Our identification of PKC!-mediated phosphorylation of RalB also establishes 
another basis for the distinct functional roles of RalA and RalB. Thus, in addition to the 
differential membrane targeting and subcellular localization information conferred by the 
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HV sequences of RalA and RalB, these sequences also determine their regulation by 
distinct protein kinases.  While the downstream consequences of Aurora-A 
phosphorylation of RalA and PKC! phosphorylation of RalB occur in similar categories 
(increased GTP-loading, translocation from the plasma membrane to endomembranes, 
differential effector association), the distinct mechanism of regulation and cellular roles 
of these protein kinases clearly add further diversity to RalA and RalB function. During 
the course of our studies, Theodorescu and colleagues described RalB phosphorylation at 
S198 by PKC [44]. They additionally showed that S198 phosphorylation was required for 
RalB support of bladder carcinoma cell line anchorage-independent growth, cell motility 
and actin organization in vitro, and tumorigenic growth and metastasis in vivo. However, 
this study did not address the consequences of S198 phosphorylation to the biochemical 
and functional properties of RalB.  Our study thus helps to explain how PKC 
phosphorylation of RalB can promote those biological outcomes. 
Several members of the PKC family of kinases have been implicated in vesicle 
trafficking, particularly in neuronal systems [119]. PKC isoforms have been shown to 
phosphorylate not only the SNARE [120] proteins but also components of the exocyst 
[121]. In this study we propose that PKC also phosphorylates RalB on S192 and S198 in 
the C-terminal HV membrane-targeting sequences. This phosphorylation event results in 
the internalization of RalB from the plasma membrane to internal membranes and a 
change in RalB effector utilization. Whereas phosphomimetic S192/198D RalB displayed 
preferential association with RalBP1, phosphodeficient S192/198A RalB showed an 
enhanced association with Sec5 and the exocyst complex.  Although it is possible that 
S198 phosphorylation may alter RalB intrinsic affinity of binding to effectors, we suspect 
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that this switch in effector interaction is most likely due to the phosphorylation-mediated 
change in RalB subcellular localization. In our previous studies of RalA phosphorylation, 
we also observed that phosphorylation promoted a change both in RalA subcellular 
localization as well as in effector association. 
 This switch in effector utilization upon RalB phosphorylation represents a 
potential mechanism through which RalB can regulate both exocytic traffic, through Sec5 
and the exocyst, and endocytic pathways, through RalBP1. Consistent with 
phosphorylation of RalB regulating vesicle sorting, we found that RalB may need to 
cycle between phosphorylation states for proper vesicle fusion and delivery of cargo 
proteins to the cell surface. Nonphosphorylated S192/198A RalB displayed a modest 
reduction in SNARE engagement and vesicle fusion while phosphomimetic S192/198D 
RalB nearly abolished VAMP3/SNAP-23 SNARE complex formation and vesicle fusion. 
This is likely due to the internalization of S192/198D RalB containing vesicles 
effectively sequestering the v-SNARE VAMP3 from plasma membrane where SNAP-23 
resides.  PKC-mediated phosphorylation of both Sec5 [121] and SNAP-23 [122] is 
critical in regulating proper exocytic vesicle fusion in various cell types.  Our work 
indicates that RalB GTPase phosphorylation in addition to SNARE and exocyst 
phosphorylation is necessary for efficient exocytosis, thus expanding the number of PKC 
substrates involved in exocytosis. 
A reduction in RalB-mediated delivery of exocytic vesicles prompted us to 
examine potential cargo proteins that may have altered expression on the cellular surface 
due to an impaired RalB phosphorylation cycle. To date, only a few proteins have been 
shown to be regulated by Ral-regulated exocyst trafficking and include E-cadherin [28], 
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GLUT4 [123], and !5-integrin [118]. Due to the known involvement of RalB in 
regulating cellular motility we chose to examine !5 as a putative protein whose sorting 
may be regulated by RalB phosphorylation. We found that RalB and !5 co-trafficked on 
endosomes containing the v-SNARE VAMP3 and that RalB may need to undergo a 
dynamic phosphorylation cycling in order to complete the delivery of !5 to the cell 
surface. This impairment in !5 surface expression in turn impaired CRC cell attachment 
to fibronectin. We suspect that additional proteins will also show RalB phosphorylation-
dependent trafficking that may contribute to the role of phosphorylation in regulating the 
function of RalB in CRC tumor cell behavior.  Finally, we also found that 
phosphorylation altered RalB association with RalBP1, and we anticipate that their 
enhanced association also contributes to the activities of phosphorylated RalB. However, 
a full understanding of how phosphorylation regulates RalB function will require 
proteomic analyses of RalB binding partners whose interactions are controlled by 
phosphorylation.   
Exocytosis is highly regulated in mammalian cells, with distinct cellular protein 
complexes necessary for vesicle trafficking, docking, and fusion at plasma membrane 
sites of exocytic delivery. The exocyst complex plays a key role in specifying plasma 
membrane sites for exocytic vesicle docking [124]. At these sites, the exocyst facilitates 
the association of v-SNARE proteins with their t-SNARE partners present on the inner 
surface of the plasma membrane. This association of SNARE proteins is thought to allow 
for the fusion of exocytic vesicles by bringing the vesicle membrane in close proximity to 
the plasma membrane [125]. Small GTPases of the Ras superfamily including the Rab 
and Ral proteins are required for proper exocytosis [28]. Rab proteins help to tether the 
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exocyst complex to secretory vesicles [126] while the Ral proteins are necessary for 
exocyst holocomplex formation [31]. Little is known about how the Ral proteins 
disengage the exocyst upon vesicle docking to allow for proper vesicular fusion to occur. 
We propose that a phosphorylation cycle is necessary for RalB to dynamically regulate 
vesicle sorting and that PKC! is a key kinase involved in this process (Figure 3-5). The 
phosphatase that would also be necessary to dynamically regulate the RalB 
phosphorylated state remains to be found. Interestingly, there is an exocyst-associated 
phosphatase [121], but whether or not this phosphatase acts on RalB is unknown. Overall, 
dynamic regulation of RalB phosphorylation serves as a mechanism through which the 
vesicle trafficking machinery can be recycled, thereby ensuring a proper flow of exocytic 
vesicles. 
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FIGURE  3-5. Model for RalB-regulated vesicular fusion. RalB is associated with the 
exocyst through its interaction with Sec5. The exocyst is docked to specific sites of vesicle 
fusion on the plasma membrane marked by the two additional exocyst components, Sec3 and 
Exo70. RalB-regulated exocyst docking occurs at fusion sites (Step 1). RalB is subsequently 
phosphorylated by PKC!, leading to disengagement from Sec5 and the exocyst (Step 2). This 
disengagement allows for the v-SNARE VAMP3 to interact with its t-SNARE SNAP23 (Step 3) 
just prior to fusion. Vesicular fusion occurs (Step 4), leading to the surface expression of cargo 
proteins like !5-integrin (Step 5). Phosphorylation of RalB signals for its internalization where it 
can then be dephosphorylated to participate in a new round of vesicle delivery. 
  
 
 
CHAPTER 4 
Ral and Rheb GAPs Integrate mTOR and GTPase Signaling in Ageing, Autophagy and 
Tumor Cell Invasion
1
 
 
Overview 
Diverse environmental cues converge on and are integrated by the mTOR 
signaling network to control cellular growth and homeostasis. The mammalian Tsc1-Tsc2 
GTPase activating protein (GAP) heterodimer is a critical negative regulator of Rheb and 
mTOR activation. The RalGAP!-RalGAP" heterodimer shares sequence and structural 
similarity with Tsc1-Tsc2. Unexpectedly, we observed that C. elegans expresses 
orthologs for the Rheb and RalA/B GTPases, and for RalGAP!/" but not Tsc1/2. This 
prompted our investigation to determine whether RalGAPs additionally modulate mTOR 
signaling. We determined that C. elegans RalGAP loss decreased lifespan, consistent 
with a Tsc-like function. Additionally, RalGAP suppression in mammalian cells caused 
RalB-selective activation and Sec5- and exocyst-dependent engagement of mTORC1 and 
suppression of autophagy. Unexpectedly, we also found that Tsc1-Tsc2 loss activated 
RalA/B independently of Rheb-mTOR signaling. Finally, RalGAP suppression caused 
                                                
1
 Authors:  Timothy D. Martin, David J. Reiner,  Xiao-Wei Chen,  Alan R. Saltiel,  Cheryl L. Walker,  and 
Channing J. Der.  All data represent the work of Timothy D. Martin except Figures 1B and 1C. 
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mTORC1-dependent pancreatic tumor cell invasion. Our findings identify an unexpected 
crosstalk and integration of the Ral and mTOR signaling networks. 
 
Introduction 
Mechanistic target of rapamycin (mTOR) signaling has emerged as a major 
signaling node that is aberrantly activated in cancer, diabetes, and neurodegenerative 
disorders [127]. mTOR is an atypical serine/threonine protein kinase that forms two 
distinct signaling complexes, mTORC1 and mTORC2, that are distinguished primarily by 
their association with Raptor or Rictor, respectively. mTORC1 but not mTORC2 is 
inhibited by rapamycin, with two analogs approved for cancer treatment. Although 
considerable advances have been made in understanding the signaling mechanisms that 
regulate mTOR activity, many unresolved and poorly understood issues remain [128]. 
 mTORC1 activity is regulated by diverse extracellular stimuli that include growth 
factors and amino acids [127]. A major upstream regulator of mTORC1 is the tuberous 
sclerosis complex comprised of the Tsc1 (aka hamartin) and Tsc2 (aka tuberin) 
heterodimer. Tsc1/2 acts as a GTPase activating protein (GAP) for the Rheb small 
GTPase by converting active Rheb-GTP to inactive Rheb-GDP [129, 130]. Rheb-GTP 
associates with and facilitates the localization and activation of mTORC1 at the 
lysosomal surface in response to nutrients [129]. Growth factors such as insulin and 
insulin-like growth factor are important stimuli of the phosphoinositide 3-kinase (PI3K) 
and Ras small GTPase pathways [131, 132], activating the Akt and ERK serine/threonine 
kinases, respectively, that directly phosphorylate and inactivate Tsc1/2, leading to 
hyperactivation of Rheb and enhanced mTORC1 signaling. Tsc1/2 is also mutationally 
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inactivated or lost in cancers, in particular renal [133] and bladder [134] cancer and non-
malignant hamartomas [135]. In contrast, amino acid activation of mTORC1 is 
independent of Tsc1/2 and instead is mediated through the Rag small GTPases. While 
clinically relevant functions of Tsc1/2 that are independent of Rheb and/or mTORC1 
have been described, the mechanisms thereof are unidentified [136]. 
mTORC1 activation regulates diverse cellular processes that include the 
stimulation of protein synthesis through direct phosphorylation and activation of S6 
kinase 1 (S6K) and inactivation of 4E-BP1. mTORC1 also negatively regulates cellular 
catabolic processes like autophagy, the central cellular degradative process for recycling 
cellular building blocks. mTORC1 signaling has also been implicated in the ageing 
process, with genetic or pharmacologic suppression of TOR extending lifespan in C. 
elegans, Drosophila, yeast, and mice [127, 137]. In C. elegans, TORC1 inhibition-
mediated lifespan extension depends on activation of the transcription factor 
FOXO/DAF-16. FOXO is also a convergence point with insulin signaling and ageing 
regulation; the C. elegans InsR/DAF-2 activates a PI3K-PDK-Akt cascade to inhibit 
FOXO activity, thereby decreasing lifespan. 
Although described originally as a tuberin-related protein (TULIP1; [138], 
RalGAP!1 and its closely related isoform, RalGAP!2, were independently discovered 
later as GAPs for the RalA and RalB small GTPases [19, 20]. The RalGAP!1 and !2 
GAP catalytic domains share significant sequence identity with the GAP catalytic domain 
of Tsc2 (26-27% identity). Furthermore, similar to the requirement for Tsc1 association 
with Tsc2 for GAP activity, the RalGAP! catalytic subunits require heterodimerization 
with a common regulatory RalGAP" subunit (aka RGC1) for their GAP activities. C. 
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elegans expresses orthologs of human Ras (LET-60), Rheb (RHEB-1) and Ral (RAL-1), 
as well as other components of Ral effector [139] and TOR signaling [127, 137]. 
Strikingly, C. elegans expresses RalGAP ! and " but not Tsc1 and Tsc2 orthologs.  This 
contrasts with Drosophila, which expresses orthologs of Rheb and Ral, as well as of 
Tsc1/2 and RalGAP!/" (Figure 4-1 A). Collectively, these observations prompted our 
interest in determining whether RalGAPs may serve as a point of integration of the Ral 
and mTOR signaling networks.  
In this study we have established that GAPs for Ral and Rheb facilitate the 
integration of Ral and mTOR signaling networks to control ageing, autophagy and tumor 
cell invasion.  First, we identified the RalGAP complex, acting through inhibition of 
RalB, as a novel negative regulator of mTORC1 signaling through Sec5 and the exocyst 
complex. Second, we identified the Tsc1/2 RhebGAP as an mTORC1-independent 
negative regulator of both RalA and RalB. Third, loss of either C. elegans RalGAP ! or " 
orthologs phenocopied TORC1 activation and decreased lifespan, consistent with 
derepression of TORC1, suggesting that in C. elegans RalGAP substitutes for the critical 
regulatory role of the Tsc complex. Finally, we showed previously that RalB activation 
drives pancreatic cancer invasion and metastasis [59], and in this study we further show 
that RalB-mediated mTORC1 activation is critical for this activity. In summary, our 
observations establish an unprecedented signaling crosstalk between the Ras-Ral and 
Rheb-mTOR signaling axes, mediated in part through their structurally similar 
heterodimeric GAP complexes. Our study suggests that rapamycin analogs may be a 
therapeutic approach for Ras-driven tumors that are dependent on RalB activity and that 
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Ral activation needs to be considered for full understanding of the clinical consequences 
of Tsc1/2 loss in human disease. 
 
Materials and Methods 
Cell Lines and Reagents 
All cell lines were obtained from ATCC and maintained according to their specifications.  
Tsc-deficient MEFs were obtained from E. Henske (Harvard) and were maintained in 
DMEM-H supplemented with 10% FCS. 
 
Expression Constructs 
pLKO.1 puro shRNAs for Raptor (1857 and 1858) and Rictor (1853 and 1854) were 
obtained from Addgene and pLKO.1 puro shRNAs for RalA, RalB, and non-specific (NS) 
control have been described previously [47].  pRK7 myc-mTOR (1861), pRK7 myc-
Raptor (1859), pRK5 myc-Rictor (1860), pRK5 HA-Raptor (8513), pRK7 FLAG-Tsc2 
(14219) were obtained from Addgene.  pCDNA3 mCherry RalB and pBabe RalB WT, 
S28N, and Q72L have been described previously [47].  pCMV Myc-RalGAP!1 has been 
described previously [20].  pEGFP-LC3 (24920) was obtained from Addgene and the 
GFP-LC3 cDNA sequence was subcloned into the lentiviral expression vector pCDH 
EF1 IRES puro using the EcoRI and BamHI sites.  Mouse and human shRNA expression 
vectors were from The RNAi Consortium (TRC) and were obtained from the UNC lenti-
shRNA Core Facility.  The TRC numbers for the mouse RalB shRNAs were 
TRCN0000077743, TRCN0000077745, and TRCN0000077747, respectively.  The TRC 
numbers for the mouse Rheb1 shRNAs were TRCN0000075603, TRCN0000075604, and 
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TRCN000007565 respectively.  The TRC numbers for the human RalGAP! shRNAs 
were TRCN0000150848 and TRCN0000156117.  All constructs were verified by 
sequencing. 
 
Antibodies 
Antibodies for western blot detection of mTOR, Raptor, Rictor, phospho-T389-S6K, S6K, 
Tsc2, p62, LC3B, HA and Myc epitope tags (Alexa Fluor488 conjugated) were from Cell 
Signaling, and for RalB and Rheb1 were from Millipore.  Antibody for western blot 
detection of RalA was from BD Biosciences, and for GAPDH, vinculin, and !-actin were 
from Sigma, for Myc was from Roche, and HA was from Covance.  Rabbit polyclonal 
antibodies for blot detection of RalGAP!, RalGAP"1, and RalGAP"2 have been 
described previously [20]. 
 
Immunofluorescence and Microscopy 
HEK293T cells were plated on 0.01% poly-L-lysine (Sigma) coated glass 
coverslips, fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100, 
then incubated with primary antibodies, followed by an Alexa Fluor-conjugated 
secondary antibody (Invitrogen). All images were acquired with sequential scanning with 
a Zeiss LSM 510, LSM 700, or LSM 710 confocal microscope.  
 
Ral Activation Assays 
Active GTP-bound Ral was isolated from whole cell lysate using GST-Sec5 Ral binding 
domain (RBD).  One hundred micrograms of total protein was rocked with 30 ug of GST-
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Sec5 RBD for 1 h at 4°C.  Beads were washed 3 times with lysis buffer and resuspended 
in 2X protein sample buffer with !-mercaptoethanol.  Samples were boiled for 5 min and 
were then loaded onto 12% SDS-PAGE gels.  Active RalB was determined by 
immunoblotting. 
 
Invasion Assays 
Matrigel invasion chambers were from BD Biosciences and all assays were 
performed in triplicate. One x 10
5
 cells per well were added and were allowed to invade 
for 24-36 h using 10% FCS as a chemoattractant.  
 
Immunoprecipitations and western blotting 
Cells were harvested and lysed in CHAPS lysis buffer (0.3% CHAPS, 50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 10 mM MgCl2, 50 mM !-glycerophosphate) containing protease 
(Roche) and phosphatase (EMD Millipore) inhibitors.  Lysates were spun for 10 min at 
14,000 RPM and protein concentrations were determined by a Bradford assay.  Protein G 
dynabeads were preloaded with the immunoprecipitating antibodies overnight prior to 
lysate addition.  Lysates were incubated with the antibody/beads for 2-4 h at 4°C.  Beads 
were then washed 3 times with CHAPS lysis buffer before being resuspended in 2X 
protein sample buffer with !-mercaptoethanol.  Beads and total lysates were boiled for 5 
min at 95°C and spun at 14,000 RPM for 1 min prior to SDS-PAGE.  Proteins were 
separated on either 6% or 12% SDS-PAGE gels and transferred to PVDF membranes for 
either 2 h at 70V or overnight at 22 V.  Blots were then blocked in 5% milk/TBST for 1 h 
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at room temperature prior to primary antibody addition.  Primary antibodies were 
incubated overnight at 4°C and developed via chemiluminescence. 
 
C. elegans Ageing Assays 
DV2729 daf-2(e1370); eri-1(mg366) animals were grown at 15°C to bypass dauer 
formation, and washed and plated without food. Late L4 animals were picked to RNAi 
plates at 25°C (day 0) and survival was assessed daily thereafter. Animals that died with 
eggs hatching within, a common trait of daf-2 mutants grown at 25°C, were removed 
from plates and not included in the final tally. However, the egg-laying defect was 
mitigated by the presence of the eri-1 mutation, which confers RNAi hypersensitivity and 
small brood size at 25°C [140]. RNA interference was performed using a standard 
protocol [141]. HT115 bacteria were grown harboring plasmids expressing dsRNA 
corresponding to gfp [10], daf-16 (I-5M24), hgap-1 (I-7B15), and hgap-2 (II-6E14). 
 
Results 
 
Ageing in C. elegans is controlled by RalGAP signaling 
The strong GAP domain sequence identity (26-27%) and same heterodimeric 
complex requirement for the catalytic activities of the RalGAPs and the Tsc1-Tsc2 
RhebGAP (Figure 1A) prompted us to examine whether they may exhibit functional 
similarities. To test this model we searched for a model experimental organism that lacks 
the RalGAP or Tsc/RhebGAP complex. We observed that while C. elegans expresses 
orthologs of human Ral (RAL-1) and Rheb (RHEB-1) along with orthologs of the 
RalGAP catalytic ! (HGAP-1) and regulatory ! (HGAP-2) subunits, notably C. elegans, 
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alone among major metazoan model organisms, lacks orthologs of either Tsc1 or Tsc2 
(Figure 4-1A). Evolutionary loss of a critical regulatory protein complex like Tsc1/2, 
which is otherwise conserved from yeast to humans [136], would have dire fecundity 
consequences unless another ancestral protein substituted for this function.  
Since Tsc1/2 are known to modulate mTOR signaling to control ageing in a 
number of animal species [127, 137], we sought to determine if RalGAPs could function 
similarly in C. elegans. Reduced function (rf) of the insulin/IGF receptor ortholog DAF-2 
results in doubled lifespan due to decreased energy utilization, which in turn is 
completely suppressed by loss of FOXO/DAF-16 [142-145]. As expected, positive 
control daf-16(RNAi) reduced daf-2(rf) lifespan compared to negative control GFP RNAi 
(Figures 4-1B). We determined that RNAi suppression of RalGAP!/HGAP-1 or 
RalGAP"/HGAP-2 also significantly reduced daf-2(rf) lifespan, consistent with 
derepressed Tor activity; C. elegans RHEB-1 and the TORC1 complex (TOR/LET-363 
and Raptor/DAF-15) promote biosynthesis and decrease longevity [127, 137]. That RNAi 
targeting of either hgap-1 or hgap-2 caused similar consequences is consistent with the 
requirement for both subunits for a functional RalGAP [19, 20] as well as the RhebGAP 
activity of the Tsc1/2 complex [146]. Due to the lack of biochemical biomarkers to study 
this process in C. elegans, we pursued further analysis in mammalian cell models, where 
there are well-established assays to access both mTOR and Ral signaling. 
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Figure 4-1. RalGAP loss reduces the increased longevity of DAF-2 deficient C. elegans  
A, C. elegans lack Tsc1 and Tsc2 orthologs but possesses orthologs for both RalGAP! and 
b. Comparison of domain structure of Rheb and Ral GAP catalytic and regulatory  subunits 
between H. sapiens, D. melanogaster, and C. elegans. Note that there are no C. elegans orthologs 
of Tsc1 and Tsc2. Numbers indicate amino acid lengths. B, RNAi-mediated knockdown of C. 
elegans RalGAP subunit orthologs reduces lifespan. Animals were allowed to feed ad libitum and 
were grown at 25°C with no caloric restrictions (left). Quantitation of lifespan from animals 
(right). Bars represent average lifespan of the indicated group. P values from a Kruskal-Wallace, 
Dunn one-way ANOVA test. 
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RalGAP signaling controls mTORC1 activity 
Loss of Tsc1 or Tsc2 causes enhanced Rheb-GTP formation and results in 
increased mTORC1 activity [127]. Since we observed that C. elegans RalGAP promotes 
longevity similarly to Tsc1/2 in other animals, we tested whether RalGAP could 
modulate mTOR signaling in mammalian cells. We isolated and analyzed mouse 
embryonic fibroblasts (MEFs) isolated from RalGAP!fl/fl conditional knockout embryos. 
Upon ectopic Cre recombinase expression and RalGAP! deletion there was a marked 
decrease in RalGAP! protein expression and increased RalA and RalB GTP-loading 
(Figure 4-2 A). There was also a large increase in the phosphorylation of the well-
validated mTORC1 substrate, S6K on T389 (pS6K; Figure 4-2A) suggesting an increase 
in mTORC1 activity in response to RalGAP! loss. Rapamycin treatment ablated pS6K 
formation in both empty and Cre treated cells, consistent with a role for mTORC1 in 
regulating the increase in pS6K upon loss of RalGAP! (Figure 4-2B). HEK293T cells 
expressing RalGAP! shRNA also showed an enhancement in pS6K (Figure 4-2C) even 
when starved of the extracellular stimuli that activate mTOR, including serum, amino 
acids, and glucose. 
 Enhanced activity of mTORC1 suppresses autophagy [147]. Using RalGAP!fl/fl 
MEFs we examined whether the enhanced mTORC1 activity seen upon loss of RalGAP! 
was associated with a reduction in autophagy. We utilized three widely used markers of 
autophagy: blot analyses to monitor the degradation of endogenous p62 (aka SQSTM1), 
the formation of the processed form of endogenous LC3 (LC3B-II), and fluorescence 
imaging analysis of MEFs with ectopically expressed GFP-tagged LC3 to monitor 
punctae formation [148]. Cre recombinase-induced loss of RalGAP! expression was 
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accompanied by an increase in p62 and a decrease in the LC3BII protein levels (Figure 4-
2D). These changes were accompanied by the appearance of fewer GFP-LC3 punctae 
(Figure 4-2E and F) signifying a reduction in autophagy. 
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Figure 4-2. RalGAPs regulate mTORC1 signaling 
A, RalGAP!-deficient MEFs have elevated Ral GTPase and mTORC1 activity. MEFs derived 
from conditional knockout RalGAP!fl/fl mice were treated with either empty or Cre recombinase 
expressing adenovirus. Cell lysates were analyzed for pS6K and for RalA- and RalB-GTP levels 
by a GST-Sec5-RBD pulldown assay. B, Elevated pS6K in RalGAP! deficient MEFs is 
dependent on mTORC1 activity. RalGAP!fl/fl MEFs treated with empty or Cre recombinase 
expressing adenovirus from (A) were treated with either vehicle control or 20 nM rapamycin for 
16 h. Cell lysates were resolved by SDS-PAGE and analyzed by immunoblotting with the 
indicated antibodies. C, Knockdown of RalGAP! in HEK293T cells results in elevated mTORC1 
activity. HEK293T cells stably transduced with the indicated lentiviral shRNA constructs were 
starved of serum, glucose, and amino acids for 1 h. Cells were then either untreated (-) or treated 
with 10% fetal calf serum (+) for 20 min. Cells lysates were immunoblotted with the indicated 
antibodies. D, Depletion of RalGAP! results in reduced autophagy. RalGAP!fl/fl MEFs were 
treated with empty or Cre recombinase expressing adenovirus followed by stable expression of 
GFP-LC3. Cells were harvested and lysates were immunoblotted with the indicated antibodies. E, 
Depletion of RalGAP! results in reduced LC3 punctae. RalGAP!fl/fl MEFs from (D) were 
analyzed for GFP-LC3 puntae. Quantitation of GFP-LC3 punctae (n = 15) is shown in the bar 
graph. p-values were determined by an unpaired Student’s t-test. 
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The RalB GTPase associates with mTOR and regulates mTORC1 signaling in ageing, 
autophagy and tumor cell invasion 
The Rheb GTPase, when bound to GTP, directly engages mTORC1 and promotes 
mTOR kinase activity and signaling [127]. The Tsc1/2 complex possesses RhebGAP 
activity to directly antagonize Rheb-mTOR signaling [149]. Since we found that the 
RalGAP complex also modulated mTORC1 activity, we investigated whether this was 
through Ral GTPase regulation. Since RalGAP did not show GAP activity for Rheb in 
vitro [19, 20], we speculated instead that mTOR is an effector of activated Ral. First, we 
determined if Ral can associate with mTOR. Using ectopically expressed proteins in 
HEK293T cells, we found that Myc-tagged mTOR co-precipitated with wild-type (WT) 
and, to a greater extent, constitutively GTP-bound RalB(Q72L) but not the dominant-
negative constitutively GDP-bound RalB(S28N) mutant (Figure 4-3A). The GTP-
dependent nature of this association is consistent with mTOR serving as an effector of 
activated RalB.  
Interestingly, expression of RalB(S28N) led to a decrease whereas RalB(Q72L) 
caused an increase in pS6K levels (Figure 4-3A) suggesting that the association of 
activated RalB with mTOR could modulate the activity of mTORC1. Surprisingly, the 
same analyses with the related RalA isoform (82% identity) that shares effectors with 
RalB [103, 150] did not show association with mTOR, indicating a unique role for RalB 
in modulating mTOR downstream of RalGAP. Supporting the physiological significance 
of this association, we also determined that endogenous mTOR and Raptor (but not 
Rictor or other mTORC2 components) co-immunoprecipitated with endogenous RalB, 
and this association was enhanced by serum but not amino acid stimulation (Figure 4-3B). 
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The association of RalB with mTOR was dependent on the expression of Raptor but not 
Rictor (Figure 4-3C) further indicating a role for RalB in regulating mTORC1 but not 
mTORC2 signaling. 
 Due to the enhanced association of RalB with mTOR in response to serum 
stimulation (Figure 4-3 B), we next addressed whether RalB was necessary for serum 
stimulated activation of mTORC1. Stable shRNA depletion of RalB but not RalA 
resulted in diminished serum stimulation of pS6K formation (Figure 4-3D) indicating the 
necessity of RalB for serum-stimulated mTOR activation, and consistent with the ability 
of RalB but not RalA to associate with mTOR. 
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Figure 4-3. RalB associates with mTORC1 and regulates mTORC1 signaling 
A, Active, GTP-bound RalB associates with mTOR. HEK293T cells expressing the indicated 
HA-tagged RalB proteins and Myc-tagged mTOR were subject to anti-HA immunoprecipitation. 
After SDS-PAGE, association of HA-RalB with myc-mTOR was determined by western blotting 
with anti-Myc. Total cell lysates were probed with the indicated antibodies, with anti-vinculin to 
verify equivalent input of total cellular protein and anti-pS6K to determine mTORC1 activity. B, 
Endogenous RalB associates with mTORC1 upon serum stimulation. HEK293T cells were 
starved of amino acids, serum, and glucose for 1 h. Cells were then either untreated (-) or treated 
with serum to a final concentration of 10% (+) for 20 min. Lysates were subject to IP with an 
anti-RalB antibody. RalB-mTORC1 complex formation was determined by western blotting. C, 
Raptor is necessary for RalB to associate with mTOR. HEK293T cells stably transduced with 
shRNA constructs for Raptor and Rictor were subject to IP anti-RalB antibody. RalB-mTOR 
complex formation was determined by western blotting. D, RalB is necessary for mTORC1 
response to serum stimulation. HEK293T cells stably transduced with shRNA constructs for 
RalA or RalB were starved of amino acids, serum, and glucose for 1 hr. Cells were then either 
untreated (-) or treated with serum to a final concentration of 10% (+). Lysates were analyzed by 
immunoblotting with the indicated antibodies. 
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The tuberous sclerosis complex (TSC) regulates Ral GTPase signaling 
We next addressed whether Tsc1 and Tsc2 could also regulate Ral activation. 
First, we ectopically expressed the catalytic RalGAP!1 subunit in Tsc2-null (-/-) MEFs 
and found that RalGAP!1 expression resulted in a decrease in mTORC1 activity, as 
indicated by a reduction in pS6K, that was comparable to that seen upon re-expression of 
Tsc2 (Figure 4-4A). We reasoned that the ability of RalGAP!1 to rescue the Tsc2 
deficiency was due to altered Ral GTPase activity and not due to changes in Rheb 
activity since the RalGAP proteins do not act upon Rheb [19, 20]. Examination of Ral 
GTPase activity in Tsc1 or Tsc2 knockout MEFs found that the GTP-bound levels of 
both RalA and RalB were elevated (Figure 4-4B). We also observed an increase in total 
cellular levels of both RalA and RalB in the Tsc2-deficient MEFs (Figure 4-4 B). We 
treated both Tsc2 WT (+/+) and null (-/-) MEFs with rapamycin and found that blocking 
mTORC1 function did not result in changes to RalB-GTP levels, indicating that the 
enhanced mTORC1 activity in Tsc2-null cells is not responsible for the enhancement in 
Ral activity (Figure 4-4C). Knockdown of Rheb1 in these same Tsc2-null cells decreased 
pS6K but not RalB-GTP levels, further implicating a Rheb-mTOR-independent 
mechanism for Tsc2 regulation of Ral activity. To address the necessity of RalB to the 
enhanced mTORC1 activity in Tsc2-null cells, we used stable shRNA expression to 
deplete RalB or Rheb1. Loss of either RalB or Rheb1 resulted in a similar decrease in 
mTORC1 activity (Figure 4-4D).  
Lastly we used tissue from the Eker rat, which carries a germline deletion of one 
Tsc2 allele, to determine whether there was altered Ral signaling associated with Tsc2 
loss in vivo. With somatic loss of the wild type Tsc2 allele, Eker rats develop 
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spontaneous tumors in various tissues, including the kidney [151]. We assessed the levels 
of RalB activity in both normal kidney and renal tumor tissue, which had reduced levels 
of Tsc2, and found increased total RalB and RalB-GTP levels in the tumors (Figure 4-4E). 
This result suggests that renal tumor formation is driven in part by RalB activation. 
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Figure 4-4. The Tuberous-Sclerosis complex (TSC) regulates Ral GTPase signaling 
A, Elevated mTORC1 activity in Tsc2-null MEFs can be rescued by RalGAP expression. Tsc2 
wildtype (+/+) and Tsc2-null (-/-) were transiently transfected with the indicated constructs. Cells 
were harvested 48 h later. B, Tsc-deficient cells have elevated Ral GTPase activity. Tsc1-null 
MEFs stably expressing either vector or Tsc1 and Tsc2 wildtype and null MEFs were subject to 
GST-Sec5 RBD pulldown assays to determine Ral GTPase activity. Pulldowns were analyzed by 
immunoblotting. C, Elevated Ral activity in Tsc2-deficient cells is not dependent on mTOR 
activity. Tsc2 wildtype or null MEFs were treated with 10 nM rapamycin for 16 h. Cells were 
harvested and subject to GST-Sec5 RBD pulldown assays to determine Ral GTPase activity. 
Pulldowns were analyzed by immunoblotting. Total cell lysates were probed with the indicated 
antibodies to determine protein expression. D, RalB and Rheb1 are necessary for elevated 
mTORC1 activity associated with Tsc2 deficiency. Tsc2
 
wildtype or Tsc2 null MEFs were stably 
transduced with shRNA contructs were starved of serum, glucose, and amino acids for 1 h.  
Lysates were analyzed by immunoblotting. E, Eker rat Tsc2-deficient tumors have elevated RalB 
activity.  Lysates from tissues from normal and tumor renal tissue were subject to GST-Sec5 
RBD pulldown assays to determine Ral GTPase activity. Pulldowns were analyzed by 
immunoblotting. *denotes non-specific bands from the pulldown assay. 
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RalB regulates serum-induced mTORC1 translocation to the plasma membrane 
Since RalB is known to play a key role in the trafficking of proteins to various 
membrane compartments [152] we determined if RalB activation could regulate 
mTORC1 subcellular localization. Localization of mCherry-RalB (mCh-RalB) and Myc-
mTOR or Myc-Raptor was examined in HEK293T cells starved of serum, glucose, and 
amino acids followed by stimulation with serum. We observed a dense perinuclear 
colocalization of RalB with both mTOR and Raptor in starved cells (Figure 4-5A and B). 
Upon serum stimulation we found that RalB was no longer perinuclear but was instead 
present at the plasma membrane, where it colocalized with both mTOR and Raptor 
(Figure 4-5A and B).  
To examine whether this change in mTOR and Raptor localization to the plasma 
membrane upon serum stimulation was dependent on RalB, we stably depleted HEK293T 
cells of RalB and examined the localization of both endogenous mTOR and Raptor in 
starved and serum stimulated cells. In control starved cells mTOR and Raptor were 
absent completely from the plasma membrane (Figure 4-5C and D). Serum stimulation 
resulted in a translocation of both mTOR and Raptor to the plasma membrane in RalB 
but not NS shRNA expressing cells (Figure 4-5C and D) demonstrating that RalB is 
necessary for the plasma membrane recruitment of mTOR and Raptor following serum 
stimulation.  
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Figure 4-5. RalB regulates serum-induced mTORC1 plasma membrane relocalization 
A, RalB and mTOR relocalize to the plasma membrane after serum stimulation. HEK293T cells 
were transfected with plasmids encoding mCherry-RalB and Myc-mTOR. Forty-eight h later cells 
were starved of amino acids, serum, and glucose for 1 h. Cells were then either untreated (-) or 
treated with serum to a final concentration of 10% (+). B, RalB and Raptor relocalize to the 
plasma membrane after serum stimulation. HEK293T cells were transfected with mCherry-RalB 
and myc-Raptor. Forty-eight h later cells were treated and processed as in (A). C, RalB is 
necessary for mTOR plasma membrane relocalization upon serum stimulation. HEK293T cells 
stably transduced with nonspecific (NS) or RalB shRNA were transfected with myc-mTOR. 
Forty-eight h later cells were starved of amino acids, serum, and glucose for 1 h. Cells were then 
either untreated (-) or treated with serum to a final concentration of 10% (+) for 20 min. D, RalB 
is necessary for Raptor plasma membrane relocalization upon serum stimulation. HEK293T cells 
stably transduced with nonspecific (NS) or RalB shRNA were transfected with Myc-Raptor. 
Arrows indicate localization at the plasma membrane. 
 
 96 
The exocyst is the RalB effector complex necessary for mTORC1 modulation 
Ral GTPases signal primarily through three main effector proteins: Sec5 and 
Exo84, two components of the Sec6/8 heterooctomeric exocyst complex involved in 
vesicle sorting, and RalBP1 (aka RLIP76) which has roles in endocytosis and actin 
reorganization [103]. To determine their possible association with mTOR, we expressed 
GFP-tagged Sec5, Exo84, or RalBP1 in HEK293T cells. We then immunoprecipitated the 
GFP-tagged effector and we found co-precipitation of endogenous mTOR with Sec5 and 
Exo84 but not RalBP1 (Figure 4-6A).  
We next used siRNA to deplete cells of either Sec5 or Exo84 to determine if 
either was necessary for RalB interaction with mTOR. Knockdown of Sec5 but not 
Exo84 caused a reduction in the coprecipitation of endogenous RalB with 
immunoprecipitated endogenous mTOR (Figure 4-6B) implicating Sec5 as the key 
effector that determines RalB-dependent mTORC1 signaling. We also found that 
depletion of Sec5 in HEK293T cells caused a reduction in pS6K levels (Figure 4-6B), 
consistent with an important role for Sec5 in facilitating RalB activation of mTORC1. 
Finally, using a variant of Sec5 with a T11A mutation that perturbs the Ral-Sec5 
association [153], we found that Ral binding is not required for Sec5 to associate with 
mTORC1 (Figure 4-6C), suggesting that activated RalB associates with a preformed but 
inactive Sec5-mTOR complex.  
Since there are exocyst-independent functions of Sec5 [33], we next determined if 
RalB-Sec5 engagement of mTOR involved the canonical exocyst complex. To address 
this question, we determined whether a non-Ral effector core component of the exocyst 
(Sec8) could also associate with mTOR. Immunoprecipitation of endogenous Sec8 also 
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displayed mTOR association independent of the presence of serum (Figure 4-6D) 
suggesting that RalB-Sec5 association with mTOR is an exocyst-dependent interaction. 
In support of this, we found that upon serum stimulation RalB and endogenous mTOR 
are found at the plasma membrane together with endogenous Sec8 (Figure 4-6E). 
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Figure 4-6. The exocyst is the RalB effector responsible for mTORC1 activity 
A, The Sec5 and Exo84 components of the exocyst interact with mTOR. HEK293T cells 
expressing the indicated GFP-tagged Ral effector proteins were subject to GFP 
immunoprecipitation and SDS-PAGE, and then immunoblotted to assess mTOR co-precipitation. 
B, Sec5 is necessary for RalB to interact with mTOR. HEK293T cells were transfected with the 
indicated siRNA pools. Forty-eight h later, cells were subject to RalB IP and immunoblotting to 
determine mTOR association. C, Ral binding is not necessary for Sec5 to associate with 
mTORC1. HEK293T cells were transfected with GFP-tagged WT or Ral binding-deficient (T11A) 
Sec5, then subjected to GFP IP followed by immunoblotting to detect mTOR and Raptor 
association. D, Endogenous Sec8 associates with mTOR. HEK293T cells were starved of amino 
acids, serum, and glucose for 1 h. Cells were then either untreated or treated with 10% serum for 
20 min, then subjected to Sec8 or normal mouse IgG immunoprecipitation followed by 
immunoblotting to determine mTOR co-precipitation. E, The exocyst is recruited with mTOR 
and RalB to the plasma membrane after serum stimulation. HEK293T cells stably expressing 
mCherry-RalB were starved of amino acids, serum, and glucose for 1 hr. Cells were then either 
untreated or treated with 10% serum for 10 min. Endogenous mTOR (green) and Sec8 (blue) 
were immunostained and co-localization with mCherry-RalB (red) was examined by confocal 
microscopy. 
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RalGAP suppresses pancreatic (PDAC) tumor cell invasive properties  
We determined previously that RalA but not RalB is necessary for pancreatic 
ductal adenocarcinoma (PDAC) anchorage-independent growth in vitro and 
tumorigenesis in vivo while RalB is necessary for PDAC invasion and metastasis in vitro 
and in vivo [59]. PDAC tumors also have elevated mTOR activity [154] and there are 
currently clinical trials evaluating mTOR inhibitors for PDAC therapy (clinicaltrials.gov). 
Therefore, we chose to examine PDAC tumor cells to assess whether the RalGAP 
proteins were important for pancreatic tumor cell growth and invasion. In a panel of 
PDAC tumor cell lines, we found expression of both RalGAP!1 and !2 in addition to the 
regulatory RalGAP" subunit (Figure 4-7A). As expected, we found that stable shRNA 
knockdown of RalGAP" enhanced the levels of both GTP-bound RalA and RalB (Figure 
4-7B). This observation was also true for shRNA depletion of RalGAP!1. We did not 
observe significant enhancement of anchorage-dependent or anchorage-independent 
growth of PDAC tumor cells following RalGAP" depletion. In contrast, knockdown of 
RalGAP" and RalGAPa1 caused a substantial increase in invasion through Matrigel 
(Figures 4-7C) likely due to the enhancement in RalB activity. 
Similar to our observations in MEFs, we also observed an increase in mTORC1 
activity when PDAC tumor cells were depleted of RalGAP" (Figure 4-7D). This led us to 
address whether blocking the enhanced mTOR activity seen upon loss of RalGAP" could 
reduce the ability of these tumor cells to invade. Treatment with rapamycin had no effect 
on the ability of PANC-1 cells expressing non-specific (NS) shRNA to invade (Figure 4-
7E). However, the increased invasion upon knockdown of RalGAP" was abolished by 
rapamycin treatment (Figure 4-7E). Since rapamycin is known to inhibit mTORC1 
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signaling, these results indicate that RalB-dependent invasion is driven in large part 
through mTORC1 signaling and potentially indicate that therapeutically targeting 
mTORC1 signaling will be of benefit in limiting the RalB-driven invasive and metastatic 
properties of pancreatic cancer. 
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Figure 7. RalGAP signaling suppresses the invasive properties of PDAC tumor cells 
A, Pancreatic adenocarcinoma cells (PDAC) express all three RalGAP proteins. PDAC tumor cell 
lines were analyzed by immunoblotting with antibodies for the indicated RalGAP subunits. B, 
Loss of RalGAP results in elevated Ral GTPase activity in PDAC cells. PDAC cells were stably 
transduced with the indicated shRNAs. Lysates were subject to GST-Sec5 RalBD pulldown 
assays to determine Ral GTPase activity. C, Knockdown of RalGAP! results in enhanced PDAC 
cell invasion. PDAC cells from (B) were treated and placed in Matrigel chambers. Numbers 
represent the average number of invaded cells per well in an assay performed in triplicate (+/- 
standard error from the mean, S.E.M). D, Loss of RalGAP results in enhanced mTORC1 
signaling in PDAC cells. PDAC cells were stably transduced with the indicated shRNAs. Lysates 
were analyzed by immunoblotting. E, Enhancement in invasion upon RalGAP! depletion in 
PDAC cells is dependent on mTOR activity. PANC-1 cells stably transduced with the indicated 
shRNAs were treated with 20 nM rapamycin for 16 h before being placed in Matrigel invasion 
chambers (left panel). Blot analysis was done to monitor pS6K levels in cell lines under the 
indicated conditions (right panel). Numbers represent the average number of invaded cells in an 
assay performed in triplicate (+/- standard error from the mean, S.E.M). p-values were 
determined by an unpaired Student’s t-test. * denotes p-value less than 0.05, ** denotes p-value 
less than 0.001, and n.s. (non-significant) denotes p-value greater than 0.05.  
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Discussion 
 
The importance of mTORC1 signaling in cancer is well-established, leading to 
successful efforts to develop mTORC1 inhibitors for cancer treatment [155]. 
Independently, there is now considerable evidence for the importance of aberrant Ral 
GTPase activation in driving cancer growth, invasion and metastasis [103, 156]. Our 
studies addressing a possible interaction between these two signaling networks, based on 
the sequence identity and structural heterodimeric complex nature of the GAPs for Ral 
and Rheb small GTPases, led us to identify an unexpected and complex crosstalk 
between Ral GTPase and mTOR signaling (Figure 4-8). For RalGAPs, we determined 
that they negatively regulate mTORC1 activation via RalB interaction with Sec5 and the 
exocyst to regulate mTORC1 subcellular localization and activity. RalGAP analysis in C. 
elegans, where the Tsc1/2 complex is absent, also supported a functional relationship 
with TOR signaling. Although Ral GTPases have well-validated roles in cancer, the 
effector functions important for these roles have remained poorly understood [103, 156]. 
Our findings suggest that mTORC1 activation is an important consequence of RalB 
activation. We additionally determined that RalB-driven pancreatic cancer invasion is 
dependent on mTORC1 activation. Surprisingly, we determined that loss of the Tsc1/2 
complex increased Ral activation. Although clinically relevant functions of Tsc1/2 
independent of Rheb-mTOR signaling have been described, the mechanistic basis for 
these activities has remained elusive [136]. We hypothesize that Ral activation is an 
important consequence of Tsc1/2 loss of function in disease. 
 We observed that C. elegans lacks bona fide orthologs of Tsc1 and Tsc2 but does 
possess a Rheb ortholog and many of the signaling components necessary for mTORC1 
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signaling found in other organisms. That C. elegans expresses orthologs of the tuberin-
related human RalGAP ! and " subunits prompted our evaluation of a possible role for 
RalGAP in mTOR signaling. A role for mTORC1 signaling in ageing and age-related 
diseases is well-established, but we still have much to learn about the molecular 
mechanisms involved. Our finding that RalGAP-directed RNAi reduced C. elegans 
lifespan is consistent with a role for RalGAP repression of Rheb-TORC1. Whether C. 
elegans RalGAP can act as a GAP for RHEB-1 or whether RAL-1 can directly interact 
with and activate TOR remain to be determined. 
 To further implicate RalGAP in regulation of mTOR signaling, we determined 
that suppression of RalGAP" in MEFs, HEK293T and pancreatic tumor cells caused 
mTORC1 activation. Our analyses established a mechanism whereby activation of RalB 
but not RalA then promotes activation of mTORC1 via Sec5 and the exocyst 
intermediary. In contrast to our findings, a previous study described a mechanism where 
RalA activation by a RalGEF then facilitated Rheb activation of mTORC1. In contrast, 
they found that growth factor activation of mTORC1 was independent of Ral activation 
[38, 157]. A second study extended this mechanism and found Rheb-dependent activation 
of the RalA effector phospholipase D involved in mTORC1 activation by nutrients [38, 
157].  Thus, both RalA and RalB can regulate mTORC1 but through distinct upstream 
stimuli and downstream effectors.  
Consistent with our findings, another study observed RalB but not RalA 
involvement in autophagy [35]. They described a mechanism whereby RalB utilizes two 
distinct exocyst subcomplexes consisting of either Sec5 or Exo84. The Exo84-containing 
complex promoted autophagy upon nutrient deprivation while starvation induced RalB-
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Exo84 complex formation. Interestingly, they also found that nutrient deprivation 
inhibited the RalB-Sec5 association. This is consistent with our finding that the RalB-
mTOR complex is both dependent upon Sec5 expression and responsive to the presence 
of growth factors. We believe our work further supports and extends their model where 
RalB can utilize two exocyst subcomplexes: one where the RalB-Sec5 interaction 
promotes mTOR activation and limits autophagy upon growth factor stimulation and 
another complex where the RalB-Exo84 complex promotes ULK1 activation to enhance 
autophagy under nutrient deprived conditions. 
Tsc1/2 regulation of Rheb is critical to keep mTORC1 signaling in check. Loss of 
function of either Tsc1 or Tsc2 leads to hyperactive Rheb and chronic mTORC1 activity, 
leading to an enhancement in cellular growth and proliferation. Despite this seemingly 
linear pathway, studies have indicated that Tsc1/2 signaling and associated biological 
properties are not exclusively dependent upon Rheb. Tsc2 GAP activity has been found 
to act on both Rab5 [158] and Rap1 [159], but in vivo characterization has been lacking. 
We found that loss of either Tsc1 or Tsc2 led to enhanced Ral GTPase activity. Since we 
have not found that Tsc1/2 displays RalGAP activity in vitro, it is unclear how Tsc1/2 
might be regulating Ral GTPase signaling. Nevertheless, we found that tumors deficient 
in Tsc2 have elevated RalB protein levels and RalB activity, indicating a potential causal 
role for RalB in Tsc1/2-deficient malignancies. Future efforts to therapeutically target 
RalB signaling potentially have promise in diseases caused by Tsc1/2 loss. 
 RalB has been shown to be involved in many important biological processes such 
as the host immune response [33], tumorigenesis [160], tumor cell invasion and 
metastasis [61, 156], control of autophagy [35] and exocytosis [47]. Despite controlling 
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such diverse biological functions, RalB is only known to interact with a limited number 
of effector proteins [161]. Recently, the exocyst proteins Sec5 and Exo84 have emerged 
as the most important effectors of RalB. We find that the exocyst engages mTOR and is 
found to colocalize with active mTOR and RalB at the plasma membrane. We speculate 
that upon growth factor stimulation, active RalB utilizes the exocyst to traffic mTORC1 
to the plasma membrane, where it can actively phosphorylate substrate proteins. This 
process may play a key role in tumor invasion and metastasis, where RalB and the 
exocyst have known roles [156]. In fact, we found that in pancreatic tumor cells with 
elevated RalB activity due to loss of RalGAP function, mTORC1 function is critical, as 
mTORC1 inhibition with rapamycin decreased invasion in vitro. Invasion and metastasis 
is largely responsible for the extraordinarily high degree of lethality associated with 
PDAC [162] and ways to block this process are of great therapeutic interest. Our finding 
that mTORC1 signaling is critical for tumor cells to invade provides a way to potentially 
inhibit RalB-driven PDAC invasion and metastasis. 
 In conclusion, we have determined that GAPs for the Ral and Rheb small 
GTPases can facilitate the convergence and interplay of two signaling networks 
previously considered distinct. That both Tsc1/2 and RalGAPs may be regulated by 
common upstream signals (e.g., AKT activation) also suggests a mechanism for the 
concurrent regulation of each GAP [163]. Previously, the importance of Tsc1/2-Rheb-
mTOR and Ral GTPases in disease had stimulated approaches to therapeutically block 
each pathway. With our finding that these are components of a shared signaling network, 
combination approaches for blocking Ral or mTOR may be more effective. 
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Figure 4-8. Working model for Ral and Rheb GAP integration of the Ral-exocyst and the 
Rheb-mTORC1 signaling networks.  In traditional regulation of mTOR by growth factors, Akt-
mediated phosphorylation of Tsc2 results in an enhancement in Rheb-GTP and an increase in 
mTORC1 activity.  We found that active RalB-GTP works through the exocyst complex to 
regulate the localization and activation of mTORC1.  Additionally, the RalGAP complex 
negatively regulates Ral activation and, as a consequence, mTORC1 activity. 
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CHAPTER 5 
Concluding Remarks and Future Directions 
 
Does Ral GTPase signaling contribute to colorectal tumorigenesis in vivo? 
 The recent characterization of RalA and RalB conditional knockout mice will 
allow for a more thorough examination of the contribution of the Ral proteins to 
oncogenesis [160].  Genetically engineered mouse models could be made where RalA or 
RalB or both could be conditionally deleted in the colon using a tissue-specific promoter 
(ie. the Villin gene promoter) to drive Cre recombinase expression.  One such mouse 
model to test the requirements of RalA and RalB to CRC is the Villin-Cre/Lox-STOP-
Lox-KRasG12V model [164].  In this model, Cre expression is driven off of the Villin 
gene promoter leading to expression of oncogenic K-Ras in the colonic epithelia and the 
formation of invasive adenocarcinomas.  This Villin-Cre/Lox-STOP-Lox-KRasG12V 
mouse could be crossed with the conditional RalA
fl/fl
, RalB
fl/fl
, or the double 
RalA
fl/fl
/RalB
fl/fl
 mouse.  Cre recombinase would be selectively expressed in the colonic 
epithelium leading to Ral gene deletion and oncogenic K-Ras expression.  If Ral is 
necessary for K-Ras driven oncogenesis in CRC, a reduction in tumor formation would 
be expected for mice deficient in Ral GTPase expression. 
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How might we therapeutically target Ral signaling for the treatment of CRC? 
Our data indicates that selective RalA inhibitors could be therapeutically useful 
for the treatment of CRC.  Currently there are only a few ways to selectively target RalA.  
Aurora-A has been shown to phosphorylate RalA on S194 but not RalB and this 
phosphorylation event is required for both Ras and Ral-driven transformation of human 
cells [43, 45].  Aurora-A is known to be upregulated in a variety of cancers including 
pancreatic (PDAC) and CRC [165, 166].  Pre-clinical evaluation of Aurora-A kinase 
inhibitors such as MLN8237 has shown a reduction in tumor formation upon Aurora-A 
inhibition [167].  Our lab has found that Aurora-A kinase inhibition via MLN8237 leads 
to decreases in the anchorage-independent growth of PDAC tumor cells and the 
tumorigenic growth of PDAC patient tumors (Nicole Neel, unpublished data).  I believe 
that Aurora-A kinase inhibitors may also be beneficial in CRC through deregulation of 
tumorigenic RalA signaling. 
Another kinase that is important for Ral GTPase signaling is CDK5.  Knockdown 
or small molecule inhibition of CDK5 leads to decreases in RalA and RalB activation in 
PDAC tumor cells [168].  This diminishment in Ral-GTP correlated with decreases in 
PDAC tumorigenesis and invasion/metastasis in an orthotopic xenograft model.  Since 
CDK5 inhibition seems to affect both RalA and RalB equally, this may not be the best 
choice for CRC.  However, with limited ways to target Ral, I believe that the 
effectiveness of CDK5 inhibition should be examined in CRC tumor cells. 
 Lastly, we may be able to selectively target RalA through inhibition of specific 
RalGEF proteins.  It is unclear which RalGEFs are important in CRC tumor cells and 
whether or not any of the RalGEFs display RalA selectivity.  Knockdown of each of the 
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six RalGEFs with RNAi and examination of cellular Ral-GTP levels would allow us to 
determine if any display preference for RalA versus RalB.  Those RalGEFs whose 
knockdown only decreases RalA- but not RalB-GTP could then be useful as therapeutic 
targets in preventing CRC tumor growth. 
 
How are Ral proteins becoming activated in CRC and are RalGEFs or K-Ras 
required for activation? 
 Our current model for how Ral is being activated in CRC tumor cells includes Ras 
activation of RalGEF proteins (Figure 2-6).  Surprisingly, I have found that transient 
depletion of K-Ras by siRNA or stable knockdown of K-Ras by shRNA in either 
colorectal (CRC) or pancreatic (PDAC) tumor cells does not significantly alter the 
activation status of either RalA or RalB.  This indicates that K-Ras is not necessary for 
the enhanced GTP-loading of Ral proteins.  This begs the question of just how Ral 
proteins are becoming activated in these tumor cells.  Expression of a dominant-negative 
RalA or RalB S28N protein that sequesters the endogenous RalGEF proteins leads to a 
decrease in cellular Ral-GTP levels indicating that RalGEFs are indeed necessary for 
endogenous Ral to become activated.  Since RalGEFs are known to interact with a 
number of small GTPases [103], I propose that we should look at other small GTPases in 
addition to K-Ras in an effort to understand how the Ral proteins become abberrently 
activated in tumor cells.  An RNAi screen to look at all GTPases that interact with the RA 
domains of the RalGEFs to facilitate Ral activation would help to determine necessary 
upstream signaling to Ral GTP-loading.  Other small GTPases known to help activate Ral 
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include H-, N-, and R-Ras, and Rap1.  Perhaps these proteins are more important in CRC 
and PDAC tumor cells for the levels of Ral activation that we observe. 
 Another possible mechanism for the high levels of Ral activation in CRC tumor 
cells could be a loss of RalGAP signaling.  This could occur through a number of 
mechanisms including downregulation of RALGAP gene transcription or mRNA 
translation or inactivation of RalGAP proteins via phosphorylation or protein degradation.  
Phosphorylation of RalGAP!2 on T715 is known to prevent the binding of Ral [20] 
leading to increases in cellular Ral-GTP.  The kinase that phosphorylates RalGAP!2 on 
T715 is Akt, a kinase that is activated downstream of oncogenic K-Ras and is required 
for K-Ras to drive transformation of fibroblasts and tumor formation in a lung cancer 
model [169].  It would be interesting to examine the phosphorylation status of T715 or 
the equivalent T736 of RalGAP!1 in tumor cells and tissue that have elevated Ral-GTP 
levels.  Inhibitors of Akt could potentially lead to an increase in RalGAP activity thus 
lowering cellular Ral activity levels providing another way to therapeutically target Ral 
GTPase signaling.  This treatment could be of importance in not only Ras-driven tumors 
but also tumors that are deficient in PTEN or have activating mutations in PI3K. 
 
Is RalB phosphorylation required for RalB-driven cancer phenotypes? 
 RalB is known to drive the migration, invasion, and growth of tumor cells.  It 
would be interesting to determine just what role phosphorylation of RalB plays in 
governing these processes.  Work done in our lab found that phosphodeficient 
S192/198A RalB mutants, when expressed in PDAC tumor cells, had impaired 
invadopodia formation and invasion through Matrigel (Nicole Neel and Timothy Martin, 
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unpublished).  RalB interacts with the exocyst to drive invasion in various tumor cell 
types and the main role of the exocyst is to regulate exocytic vesicle delivery to the 
plasma membrane.  I believe that part of the impairment in invasion seen with the 
S192/198A RalB mutant could be due to diminished exocytic flux of key proteins that 
drive invasion/metastasis.  Identification of these cargo proteins could be determined with 
a mass spectrometry approach.  RalB/exocyst-containing secretory vesicles could be 
isolated using standard subcellular fractionation techniques paired with RalB and/or 
exocyst immunoprecipitation to capture specific vesicle pools.  The proteins contained in 
these vesicles could then be analyzed by mass spectrometry.  Some expected cargo 
proteins would be !5-integrin, which we found previously to depend on RalB 
phosphorylation for proper trafficking, and perhaps matrix metalloproteases (MMPs) that 
are known to be important for PDAC tumor cell invasion since the exocyst has previously 
been shown to be important for MMP secretion [170, 171]. 
 
Does RalB phosphorylation affect novel effector interactions? 
 We found that phosphorylation could both positively and negatively regulate 
effector engagement by RalB (Figure 3-2 E and F).  It would be interesting to determine 
if the phosphorylation status of RalB was important for unknown effector interactions.  
The same phosphodeficient and phosphomimetic (S192/198A or S192/198D, respectively) 
could be used to identify interacting proteins using a co-immunoprecipitation followed by 
mass spectrometry approach.  Previous efforts to identify Ral interacting proteins relied 
on constitutively active GTP-bound mutants.  This approach using phosphorylation 
mutants may identify unknown signaling partners that are a result of altered RalB 
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subcellular localization or interaction with the RalB C-terminus due to phosphorylation.  
A more complete understanding of RalB downstream effector signaling will provide 
insight into potential ways to target RalB for therapy. 
 
How does phosphorylation of RalB regulation its activation? 
 We identified changes in RalB GTP-loading upon expression of RalB 
phosphodeficient S198A or S192/198A (Figure 3-2 A).  Additionally, we found that 
treatment with PKC agonists leads to an enhancement RalB activation.  What is unclear 
is just how phosphorylation is leading to these changes in RalB activation.  It’s possible 
that changes in RalB subcellular localization in response phosphorylation allows for 
association with RalGEF proteins.  RalGEF proteins have been found to localize to 
endosomes and Ral activation has been observed on endosomes using FRET-based 
biosensors [63, 172].  Perhaps phosphorylation is an important upstream cue to relocalize 
RalB to endosomes for activation catalyzed by RalGEF proteins.  To test this hypothesis, 
RNAi directed against different RalGEF proteins could be expressed and RalB activation 
in response to PKC agonists could be analyzed.  If RalGEF proteins are critical for the 
enhancement in RalB activation after phosphorylation, RNAi-depletion of RalGEFs 
should prevent RalB activation.   
Dominant-negative RalB S28N is a nucleotide-free mutant that will form a stable 
complex with RalGEF proteins making it possible to co-immunoprecipitate RalB S28N 
with different RalGEFs.  The phosphomimetic and phosphodeficient mutants of RalB 
described could be also be given a S28N mutation in order to examine altered association 
with RalGEF proteins.  I would predict an increase in RalB-RalGEF complex upon 
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phosphorylation if RalGEFs are indeed responsible for the activation of RalB observed 
after PKC activation. 
 
Does C. elegans HGAP-1/HGAP-2 RalGAP complex require RHEB-1 or Ral-1 to 
modulate ageing? 
 Our current data only implicate RalGAP signaling in controlling the ageing of C. 
elegans.  While we believe that this is due to altered control of Ral-1 and Rheb-1 activity, 
we haven’t directly tested this hypothesis.  One reason is that we would need to lose both 
RalGAP and either Ral-1 or Rheb-1 in worms.  Double RNAi experiments are extremely 
tricky and tough to interpret since only partial effects may be seen by using more than 
one RNAi sequence.  One way to address this would be to use a reduced function or 
RalGAP null allele and combine this with Ral-1 or Rheb-1 RNAi.  We recently obtained 
both hgap-1 and hgap-2 null worms that phenocopy what we found with feeding RNAi 
(fRNAi) of both genes.  We plan on using fRNAi of Ral-1 and Rheb-1 on these strains to 
determine if loss of either or both will reverse the reduced ageing phenotype associated 
with reduced RalGAP function.  It will be important to determine whether the GAP 
activity of hgap-1 is necessary for controlling ageing as well.  GAP assays using hgap-1 
and hgap-2 on C. elegans Ral-1 and Rheb-1 should be performed to examine whether this 
ancestral Tsc-like complex can indeed regulate both the Ral and Rheb signaling pathways. 
 While we believe that mTOR is key in controlling lifespan in C. elegans in 
response to RalGAP loss, we haven’t formally tested this and I believe that it is an 
important question to answer.  If enhanced mTOR signaling is indeed responsible for the 
reduced lifespan phenotype seen upon hgap-1 or hgap-2 loss, loss of mTOR activity 
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should rescue lifespan.  This could be accomplished in a couple of ways.  RNAi directed 
against C elegans mTOR or daf-15/Raptor would block mTORC1 function and be 
expected to rescue lifespan.  Worms could also be treated with an mTOR inhibitor such 
as rapamycin, which is known to inhibit C. elegans mTOR as well, and a rescue in 
lifespan would also be expected. 
 
Are there changes in metabolic signaling upon loss of RalGAP? 
 With our discovery that mTORC1 is regulated by RalGAP and RalB signaling, it 
will be interesting to determine if there are changes in metabolism as well.  Metabolic 
pathways have gained a lot of interest as a means to treat cancer.  Cancer is a disease that 
is defined by uncontrolled proliferation and growth.  Changes in metabolism are at the 
heart of controlling cellular growth and many metabolic pathways are deregulated in 
tumors compared to normal tissue.  The Warburg effect was originally identified in the 
1920s when it was found that there was a switch in tumor cells from using glucose for 
oxidative phosphorylation to the production of lactate.  Proliferating cells, especially 
tumor cells, seem to rely on enhanced glucose uptake and lactate production for growth. 
Since we currently have few ways to inhibit Ral GTPase activity, perhaps a new target 
could be found using a metabolomics approach. 
 Work done by Brendan Manning’s group identified a metabolomics gene 
signature associated with mTORC1 signaling [173].  They found that SREBP was a key 
transcription factor necessary for mTORC1 upregulation of lipid biosynthesis and cell 
proliferation.  It would be interesting to determine if loss of RalGAP could also 
contribute to changes in metabolism driven by mTORC1.  This could be done by doing 
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metabolomics on RalGAP!
fl/fl
 MEFs treated with Cre compared to empty adenovirus.  
Idenfication of mTORC1-dependent changes could be parsed out by also looking at 
changes that are rapamycin sensitive.  If we find that loss of RalGAP leads to metabolic 
changes dependent on Ral it would provide rationale for testing whether or not enhanced 
Ral activity is a biomarker for sensitivity to inhibitors of mTORC1-regulated metabolic 
pathways. 
 
Is mTOR inhibitor tumor response associated with RalB activity? 
 Certain tumor types such as subsets of bladder tumors and gliomas do not respond 
to rapamycin analogs (rapalogs).  In the case of gliomas, this insensitivity to rapalogs is 
attributed to compensatory mechanisms that arise upon mTOR inhibition [174].  In 
bladder tumors samples it was recently determined that mutations in TSC1 sensitized 
tumors to mTOR inhibition by the rapalog everolimus [134]. It would be interesting to 
determine whether RalB activity can play a role in dictating response to mTOR inhibition. 
In gliomas perhaps high RalB activity may protect cells from mTOR inhibition.  High 
RalB activity may be associated with enhanced mTORC1 signaling making the 
therapeutic dose ineffective at fully blocking mTORC1 function leading to a perceived 
insensitivity to mTOR inhibition. 
 In bladder tumors that have mutations in TSC1 leading to enhanced mTOR 
activity, it would be interesting to determine whether or not Ral activation is also 
enhanced.  Since we found that Tsc-deficient tumors and cell lines have highly activated 
RalA and RalB, I expect that these TSC1 mutant bladder tumors and cell lines also have 
enhanced Ral activation.  A recent study found that downregulation of RalGAP"2 
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expression was associated with enhanced Ral GTPase activity and a promotion of tumor 
cell invasion and metastasis [54].  It would be interesting to examine whether these 
bladder tumors with reduced RalGAP function have a higher level of mTORC1 signaling 
similar to what we found in PDAC tumor cells (Fig 4-6 D) and whether blocking mTOR 
activity in these cells would limit both invasion and metastasis.  I propose that we should 
examine RalGAP!2 expression in bladder cancer patients as an additional biomarker to 
TSC1 mutations status in order to predict which tumors will respond to mTOR inhibitor 
treatment. 
 
Are there novel mTORC1 substrates that are dependent upon RalB signaling? 
 It is often remarked how mTOR seems to be involved in regulating virtually every 
cellular process.  While this is obviously not the case, it is remarkable that mTOR, an 
important kinase in controlling cellular metabolism and homeostasis, only has a few bona 
fide substrates [127].  Recent studies using phosphoproteomics in response to rapamycin 
treatment identified the Grb10 adaptor protein as a mTOR substrate [175, 176] bringing 
the number of verified mTOR substrates to just four (ULK1, p70S6K, 4E-BP1, and 
Grb10).  It is hard to imagine that mTOR can perform its important role with just four 
substrates.  I propose that since Ral signaling is providing additional mTOR regulation 
we can use this in an attempt to identify novel mTORC1 substrates.  Phosphoproteomics 
could be performed using the RalGAP"
fl/fl
 MEFs that have been treated with either empty 
or Cre expressing adenovirus.  Due to an increase in mTORC1 signaling upon RalGAP" 
deletion, any changes seen in the phosphoproteome could indicate novel mTORC1 
substrates.  Of course it is possible that changes in phosphorylation are not due changes 
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mTORC1 activity but are instead another mTOR-independent effect of RalGAP! loss.  
To address this possibility, RalGAP! null cells could also be treated with rapamycin.  
This should rescue the enhancement in a subset of phosphorylated subtrates upon 
RalGAP! loss allowing for the identification of novel RalGAP!-dependent mTORC1 
substrates. 
 
Why does RalB aid in localizing mTORC1 to the plasma membrane upon serum 
stimulation? 
 A previous study found that the small GTPase Rac helped to localize mTORC1 
and mTORC2 and that this was critical for the activity of both complexes as measured by 
S6K T389 and Akt S473 phosphorylation respectively [177].  What is unclear is why 
mTOR would need to be at the plasma membrane for signaling.  It is known that there are 
large microdomains of the plasma membrane that concentrate signaling molecules, which 
increases signaling fecundity [178].  Additionally, p70 S6K activation requires functional 
lipid raft domains as inhibitors of lipid raft formation prevent mTORC1-dependent S6K 
phosphorylation.  Since we found that RalB is necessary for both mTORC1 activation 
and its delivery to the plasma membrane in response to serum, it will be interesting to 
examine why mTORC1 needs to translocate to the plasma membrane.   
One reason could be that mTORC1 substrates are localized at the plasma 
membrane thus necessitating the translocation so that mTOR can phosphorylate them.  
Evidence suggests that p70S6K is localized to the plasma membrane in response to EGF 
treatment supporting the idea that mTORC1 substrates can be found at the plasma 
membrane [179].  Work done by the Sabatini group found that a Raptor mutant that had 
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the hypervariable domain of H-Ras fused to its C-terminus was constitutively active even 
under nutrient depleted conditions[180].  This mutant of Raptor was constitutively 
associated with the plasma membrane indicating that simply localizing mTORC1 to the 
plasma membrane is sufficient for activation.  I believe that adding the C-terminal 
domain of RalB to Raptor will have a similar or even greater effect at activating 
mTORC1 activity without upstream stimuli.   
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